Protective and Pro-Inflammatory Roles of Intestinal Bacteria

Cynthia Reinoso Webb*, Iurii Kobozev*, Kathryn L. Furr and Matthew B. Grisham[#]

Department of Immunology and Molecular Microbiology
Texas Tech University Health Sciences Center
Lubbock, Texas 79430

*These authors contributed equally to the preparation of this manuscript

Running title: Microbiota, homeostasis and inflammation

Key words: commensal bacteria, zebrafish, Crohn's disease, ulcerative colitis, pathobiont, dysbiosis, T cells.

[#] Corresponding author:

Matthew B. Grisham, Ph.D.

Department of Immunology and Molecular Microbiology

Texas Tech University Health Sciences Center

3601 4th Street STOP 6591

Lubbock, Texas 79430

United States of America

Phone: 806-743-2598

Email: matthew.grisham@ttuhsc.edu

1. Introduction

The healthy human body contains 10 times more microbial cells than human cells! This proclamation has been repeated many times over the past several years in both the scientific literature, as well as the lay press [169]. Although this declaration has been presented as a scientific fact over the past decade, it may not be entirely accurate in view of a recent reexamination of the published data [169]. Most reviews that focus on host-microbe interactions begin with the statement that the healthy human intestine contains approximately 100 trillion (10^{14}) microbes [55,102,102,176,178,211]. Furthermore, many of these publications state, without reference, that the total number of human cells in the body approximates 10 trillion (10^{13}) cells [169,178]. However, this 10-fold excess of microbial to human cells may need to be reevaluated based upon more recent work that has been largely overlooked during the past few years. For example, the statement that the intestinal tract contains 10^{14} microbial cells is based upon a 44 year-old report that provides little by way of direct quantitative data for this fecal bacterial estimate [108]. Using more sophisticated technology, Suau and coworkers have determined that the numbers of bacteria that reside within the healthy human intestinal tract range from 3×10^{13} to 40×10^{13} (30 trillion to 400 trillion) [194]. The assertion that humans contain 10^{13} body cells is based upon one sentence from a 46 year-old book that provides no experimental data nor references for this estimate [37]. A recent study by Bianconi et. al. using systematic quantification of cell numbers in different tissues reports that humans contain, on average, 30-40 trillion body cells [12]. These newer data would suggest a more realistic ratio of microbial to human cells that range from 1:1 to 10:1.

While these more quantitative estimates are, in some cases, quite different from what has been repeatedly stated in scientific and lay publications, they confirm that the gut is home to enormous numbers of bacteria. The large majority (>90%) of intestinal bacteria in the human intestinal tract belongs to the phyla Bacteroidetes and Firmicutes. However, substantial numbers of bacteria belonging to phyla Proteobacteria, Actinobacteria, Fusobacteria, Verrucomicrobia and Cyanobacteria are also observed [38,40,44,102,106,176] (Figure 1). In addition to the enormous population of bacteria, the human gut has also been estimated to contain more than a quadrillion (10^{15}) viruses and bacteriophage, as well as substantial numbers of archaea and fungi [40,55,62,102,106,143,199]. Most of the detailed characterization and bioinformatic analyses of the intestinal microbiota have been performed using human stool and/or mucosal tissue. However, mice have also been extensively used to define the importance of host genetics, microbiota and the immune system in host-microbe interactions in homeostasis and disease [28,141]. The use of mice provide investigators with a small animal model to assess, in a well-controlled environment, the complex host-microbe interactions that occur *in vivo*. While mice and humans share two major phyla (Bacteroidetes and Firmicutes) and approximately 80 different genera [141,168], major differences exist among bacterial species in these two mammals [141,168].

Valuable information has been generated using gnotobiotic and fully colonized mice to assess host-microbiome interactions. However, these studies are limited by the length of time and the high cost associated with the generation of large numbers of genetically-manipulated animals required to yield statistically-powered *in vivo* studies. In an attempt to shorten the time and cost of new discoveries, investigators have begun to

use other vertebrates to model these interactions in healthy and inflamed intestine. For example, zebrafish (*Danio rerio*) have become increasingly popular for these types of studies given the similarity of their intestinal tract to that of mammals [57,208]. Although major differences exist between teleost and mammal microbiota, zebrafish share many of the major microbial communities that have been identified in rodents and humans [160,161,180,195,198]. Investigators have shown that similar to humans and mice, the teleost gut contains large numbers of Proteobacteria, Firmicutes and Bacteroidetes [30,166,195] (Figure 1). The use of teleosts offer a number of advantages over mice and other rodents due to the relatively low cost to produce and maintain large numbers of larvae and adults, their accelerated development, and their transparent skin that allows for detailed and noninvasive imaging studies [161,216]. Another major advantage of zebrafish is their amenability to produce forward and reverse genetic manipulations [216]. Furthermore, because these vertebrates live in an aqueous environment, the delivery of different chemicals/small molecules, therapeutic agents or microbiota to germ-free or fully colonized zebrafish is relatively a straight forward process [19,47,64,160,161,198].

The continuous exposure of the vertebrate intestine to such large and diverse populations of microorganisms in close proximity to a tissue that contains large numbers of immune cells, makes the gut the largest and most complex component of the immune system. The coexistence of vertebrates with their gut microbiota is a dynamic and mutually beneficial relationship that plays an important role in the well-being of the host [29]. However, the close proximity of potentially harmful/pathogenic microorganisms has forced the intestinal immune system to develop a number of different immune mechanisms to eliminate invading microbes, while suppressing the bystander tissue injury associated with these innate and adaptive immune responses. Failure to properly regulate these protective immune responses may induce chronic inflammatory responses that are thought to be critical immunopathological mechanisms responsible for the development of human inflammatory bowel diseases (IBD; Crohn's disease, ulcerative colitis). These idiopathic inflammatory diseases affect primarily the small and/or large bowel and are characterized by the infiltration of large numbers of inflammatory leukocytes (e.g. neutrophils, monocytes, and lymphocytes) into the intestinal lamina propria (LP) where they directly or indirectly promote inflammation with tissue injury, loss of goblet cells, fibrosis, erosions and ulcerations. Although the etiology of IBD remains to be defined, it is becoming increasingly appreciated that chronic intestinal inflammation may result from a complex interaction among genetic, immune and microbial factors [73,99,214]. Based upon a large body of experimental and clinical evidence generated over the past 20 years, investigators hypothesize that chronic gut inflammation results from a dysregulated immune response to components of the normal gut flora in genetically-susceptible individuals [31,79,95]. Although mouse models of IBD have been used for more than 20 years and have been instrumental in defining many of the major immunopathological mechanisms responsible for inflammatory tissue injury in these models, progress as been slow for reasons outlined above [95]. Thus, several groups of investigators have turned to the use of zebrafish to model IBD (see below) [19,47,63,64,216]. The objective of this review is to present our current understanding of the role that the intestinal microbiota play in vertebrate intestinal health and inflammation. While our primary focus will be humans and mice, we

also present the new and exciting comparative studies being performed in zebrafish to model host-microbe interactions.

2. Development of Bacterial Communities within the Intestinal Tract

The colonization and development of the intestinal microbiota in all vertebrates is crucial for the generation of a fully functional immune system, production of essential nutrients and vitamins, and metabolism of xenobiotics. While it has been assumed that the development of a stable microbiota in the mammalian gut begins at birth, since in utero the fetus has been thought to be germ-free, more recent reports suggest that this may not be the case as bacteria have been isolated from meconium, umbilical cord and amniotic fluid obtained from healthy pregnancies [81]. Nevertheless, the development of a newborn's microbiota begins following birth via the colonization of the infant's intestinal tract with bacteria associated with the mother's skin, vagina, feces, and breast milk [102,117,190]. During the first three months of life, *Bifidobacterium* and *Lactobacillus* colonize the intestinal tract in mammals due to the ingestion of breast milk [97,190]. Early on in the infant's life, the microbial communities are highly variable and relatively unstable when compared to the adult microbiota which has much greater complexity and phylogenetic diversity [97,149]. It is thought that the stabilization/maturation of the microbiota occurs at approximately 2-3 years of age and that the microbiota can be prepared with genes for the metabolism of food that is not yet being consumed by the infant (i.e. plant polysaccharide metabolism) [6,97,149,217]. Koenig et al., has shown that the assembly of the microbial communities early in life is not random, but instead, occurs by way of specific bacterial successions due to different life events [97]. The fully mature intestinal microbiota is distinctly distributed among the different parts of the gastrointestinal (GI) tract, dictated primarily by the different oxygen concentrations found within the lumen and along the length of the GI tract (Figure 2). It is well-appreciated that the more proximal portions of the GI tract (i.e. stomach, duodenum) contain much higher levels of luminal oxygen and are populated by a higher percentage of aerobic and facultative anaerobic bacteria; although total numbers of bacteria in these regions of the GI tract are much lower than those found in the distal portions of the small and large bowel [42,176]. The distal portion of the small intestine as well as the colon contains little or no oxygen, thereby facilitating the growth of obligate anaerobes [1] (Figure 2).

The early development of intestinal microbial communities in mammals contrasts that of teleosts, given their differences with respect to life cycle. For example, zebrafish egg fertilization takes place externally with embryonic development occurring within the sterile chorion. At 2 days post fertilization (d.p.f.) the larvae hatch and are released into the environment where microbial colonization begins [33,219]. As with other vertebrates, microbial colonization of the intestine serves as a potent stimulus to induce the maturation of the gut immune system and digestive functions such that the larvae may begin to ingest food at approximately 5 d.p.f. [8,219]. The development of the intestinal microbiota continues throughout life, continuously responding to changes in the environment as the zebrafish mature from larva to adult. Although little information is currently available describing the intestinal microenvironment, its luminal oxygen tension, the regional microbial composition and total bacterial load in teleosts, it has been reported that the distribution of microbial communities in the hindgut of fish is

1
2
3
4 similar to the distal bowel of mammals as they share similar communities of bacteria
5 such as Proteobacteria, Fusobacteria, Firmicutes and Bacteroidetes [30,166,187,195].
6 Once established, intestinal microbial communities in both mammals and fish may be
7 continually modified by different factors that include diet, genetics, sex and the
8 environment [36,106,120,195]. Some of these factors may induce stronger and more
9 profound changes in the microbiota, while others such as short term antibiotic use or
10 changes in diet may induce temporary shifts in the different bacterial populations and
11 that they are able to, to a certain point, return to their original state (a term called
12 resilience) [35].

13
14
15 As pointed out earlier, the gut microbiota plays an essential role in the
16 development of a fully functional immune system in both mammals and teleosts
17 [57,124,219]. Studies using germ-free mice reveal that these rodents have under-
18 developed lymphoid tissues, defective T and B cell function, and low numbers of
19 circulating CD4⁺ T cells and antibody production, all of which can be restored by
20 colonizing mice with microorganisms [28,123]. Similar findings have been described
21 using germ-free zebrafish, which lack specific aspects of gut epithelium differentiation
22 (specification and maturation) and proliferation, decreased protein macromolecule
23 uptake and altered gut motility, all of which can be reversed by the introduction of
24 intestinal microbiota [8,8,161,208]. In addition to helping shape the intestinal and
25 systemic immune system, gut microbiota are essential for providing critical metabolic
26 functions that cannot be accomplished by the host [145]. For example, some intestinal
27 bacteria (obligate anaerobes) in mammals and teleosts are capable of degrading “non-
28 digestible” complex carbohydrates (fiber) to produce short chain fatty acids (SCFA)
29 such as acetate, butyrate and propionate (Figure 2) [30,55]. These metabolites, rather
30 than glucose, are the preferred energy substrate for colonic epithelial cells. In addition,
31 certain bacteria (i.e. *Bacteroides*, *Bifidobacterium*, and *Enterococcus*) are capable of
32 synthesizing vitamins as well as degrading different xenobiotics as it has been shown in
33 humans [55,97,136].

34
35
36 The development of such dense and complex populations of microorganisms that
37 reside so close to the gut requires that the intestinal immune system maintain tolerance
38 to nonpathogenic/commensal bacteria. This is also true for teleosts whose immune
39 system has to be able to coexist with commensal microorganisms in the gut, gills and
40 skin [46]. Although the mechanisms responsible for tolerance have not been completely
41 defined, there is good evidence to suggest that interactions between commensal
42 bacteria and host mucosa induce highly regulated innate and adaptive immune
43 responses [70,175]. For example, certain commensal bacteria such as segmented
44 filamentous bacteria (SFB) have been shown to induce T helper 17 (Th17) cell
45 differentiation in the small intestine, which protects the host from fungal and bacterial
46 infections [5,76,77]. Interleukin 22 (IL-22), a Th17-derived cytokine, has been shown to
47 enhance tight junctions in epithelial cells and increase mucin and antimicrobial protein
48 production, all of which limit bacterial invasion into the lamina propria. Other bacteria
49 such as the Clostridia clusters IV, XIVa and XVIII and Bacteroidetes have been shown
50 to induce immuno-regulatory T cells called regulatory T cells (Tregs; CD4⁺Foxp3⁺ T
51 cells). These T cells are known to suppress immune responses to self and bacterial
52 antigens, promote epithelial repair, and promote tolerance to microbes [4,116,125,176].
53 In zebrafish, the intestinal microbiota also promotes the regulation of the innate immune
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4 responses to infections as reported by Galindo-Villegas et al. [51]. Furthermore, Rawls
5 and coworkers demonstrated that the zebrafish gut microbiota is important for the
6 expression of over 200 genes in the zebrafish intestine, many of which have also been
7 observed in mice and are associated with epithelial proliferation, immune responses
8 and nutrient metabolism [161].
9

10 11 **3. Protection Against Invasion of Unwanted Neighbors**

12 In mammals, the intestinal epithelial cell monolayer is composed of absorptive
13 epithelial cells as well as specialized cells (e.g. goblet cells, Paneth cells) that are
14 capable of secreting protective macromolecules and peptides. Immediately underlying
15 the epithelium is the lamina propria which contains large numbers of plasma cells that
16 produce IgA, a signature protective immunoglobulin of mucosal surfaces. Transcellular
17 transport of IgA from the LP to the bowel lumen is mediated by the polymeric
18 immunoglobulin receptor (pIgR), which is localized on the basolateral surface of
19 epithelial cells [82]. Similar to mammals, the teleost intestine consists of three visually
20 distinct anatomical divisions: the rostral intestinal bulb, the mid-intestine and the caudal
21 intestine. In contrast with mammals, zebrafish do not contain a stomach [208]. Gene
22 expression data in zebrafish suggest that the physiological functions of certain
23 segments of its intestine are similar to mammals. Molecular characterization of the
24 zebrafish transcriptome shows that the rostral and mid zebrafish intestine, where most
25 metabolism, transport of nutrients, and energy metabolism take place, are functionally
26 similar to the small intestine in mammals. In turn, the zebrafish caudal intestine is
27 analogous to the mammalian large intestine [209]. It should be noted that crypts and
28 Peyer's Patches are absent in the zebrafish gut. The intestinal monolayer in zebrafish
29 consists of three principal cell types: enterocytes, enteroendocrine cells, and goblet
30 cells [103,129,216].
31

32 Invasion of pathogenic or commensal bacteria into the gut interstitium (i.e. LP)
33 and their dissemination into the systemic circulation has the potential to produce
34 devastating immune responses that could result in systemic inflammation, illness and
35 possibly death. How does the gut limit and/or prevent the invasion of these unwanted
36 neighbors? Essentially, the intestine has evolved four major levels of distinct but
37 overlapping lines of defense that minimize contact of microbes with the intestinal
38 epithelium, as well as eradicate microbes that manage to penetrate the epithelial barrier
39 and gain access to the intestinal tissues [18,69]. The first line of defense in mammals is
40 mediated by goblet cells, which are specialized epithelial cells that produce mucin, a
41 highly glycosylated glycoprotein that polymerizes to form mucus. The macromolecular
42 gel adheres to the apical surface of epithelial cells thereby providing a physical barrier
43 that separates the epithelium from luminal bacteria [150]. The colon contains both an
44 inner and outer layer of mucus. The inner layer of mucus is dense, highly polymerized,
45 tightly adherent to the epithelial cell surface and relatively impermeable to the
46 microbiota due to its resistance to most bacterial proteases [84]. The outer mucus layer
47 is a loose, net-like polymer that occupies approximately 4 times the volume than the
48 inner layer. It is not uncommon to observe some bacteria in the outer layer of mucus
49 that may arise from limited proteolysis of the polymer that is mediated by the host as
50 well as resident bacteria [82,83].
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5 In contrast to the colon, the small intestine contains substantially smaller
6 numbers of bacteria with the epithelium being covered by a single, loosely adherent
7 layer of mucus. However, some pathogenic microorganisms have developed strategies
8 to penetrate the mucus layers, allowing them to gain access to the epithelial cell surface
9 through various strategies that vary among pathogens and commensals alike [38]. For
10 instance, YghI, an *Escherichia coli*-derived M60-like protease degrades mucus proteins,
11 thus providing bacteria with access to the mouse small intestinal epithelium [110]. Pic, a
12 secreted protease produced by *E. coli* and *Shigella flexneri*, degrades rat ileal mucus
13 and stimulates compensatory mucus hypersecretion by goblet cells [140]. In addition,
14 the food-born pathogen *Campylobacter jejuni* expresses JlpA surface lipoprotein
15 adhesin, which allows for colonization of the human small intestine and colon [91].
16 Furthermore, the gastrointestinal pathogen *Salmonella enterica* penetrates cecal mucus
17 using chemotaxis and flagella [193]. Under the highly acidic conditions of the stomach,
18 *Helicobacter pylori* may reduce mucus viscosity via alkalization of the environment
19 thereby allowing adhesion of these pathogens to the surface epithelium using SabA
20 adhesin. It is hypothesized that NH₃ that causes pH elevation is produced by *H. pylori*
21 from the hydrolysis of urea [23,115]. The importance of mucus as a protective barrier
22 has been directly demonstrated in genetically-engineered mice that have been rendered
23 devoid of intact colonic mucus via deletion of the *Muc2* gene. These *Muc2*-deficient
24 (*Muc2*^{-/-}) mice exhibit growth retardation, enhanced bacterial invasion of colonic crypts
25 and development of colonic inflammation by 5 weeks of age [202]. The absence of
26 mucus may also synergize with other genetic defects such that mice devoid of both
27 *Muc2* and the *IL-10* gene (*Muc2*^{-/-}/*IL-10*^{-/-} double deficient animals) develop exacerbated
28 colitis when compared to colitis that develops in *Muc2*^{-/-} or *IL-10*^{-/-} animals [201]. These
29 data suggest that chronic colitis in mucus-deficient mice may be due to the adhesion of
30 bacteria to colonic epithelial cells (colonocytes) and invasion of these unwanted
31 neighbors into the lamina propria where they activate innate and adaptive immune
32 responses. In reality, the mechanisms for the induction of inflammation may be more
33 complicated than simple adhesion/invasion of luminal bacteria as it is well-known that
34 certain species of bacteria are capable of adhering to epithelial cells without invading
35 the tissue or launching an intestinal inflammatory response. In fact, commensal
36 bacteria-epithelial cell interactions appear to be required for homeostasis and for
37 mediating tolerance to commensal bacteria [77,159]. The teleost intestinal tract is also
38 endowed with a single protective layer of mucus. Zebrafish possess 5 genes that code
39 expression of gel-forming mucin glycoproteins, which belong to two gene families: *Muc2*
40 (*Muc2.1* and *Muc2.2* genes) and *Muc5* (*Muc5.1*, *Muc5.2* and *Muc5.3* genes).
41 Sequencing of these genes revealed a great deal of homology to other vertebrates.
42 According to gene sequencing data, the domain architecture of *Muc5.1* and *Muc5.2*
43 zebrafish mucin proteins is typical for mammalian-secreted mucins [57,80]. The
44 importance of intestinal mucus in zebrafish was demonstrated by Oehlers et al. who
45 found that reduction of mucus secretion via administration of retinoic acid exacerbated
46 enterocolitis induced by the hapten trinitrobenzene sulfonic acid (TNBS) in zebrafish
47 larvae [146].

48 A second line of defense designed to limit the contact of bacteria with the
49 intestinal epithelium is the secretion of different antimicrobial peptides (AMPs) by
50 specialized epithelial cells (Figure 2). In general, AMPs are restricted to the mucus with
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

only minute amounts diffusing into the gut lumen [131]. Paneth cells, in spite of being a relatively rare cell type located in the intestinal crypts, are essential for limiting access of bacteria to the epithelium [11]. These specialized cells secrete α -defensins (called cryptdins in mice) which bind to bacterial cell membranes and permeabilize them, resulting in death of the microorganism. In contrast to other defensins, human α -defensin 6 (HD6) does not destroy the bacterial membrane. Instead, it forms a nano-net of self-assembling fibrils on the surface of the bacterial cell thereby interfering with its ability to bind to the epithelium [14,149,210]. Of note, mice lack the HD6 analogue [183]. It appears that the secretion of cryptdins as well as cryptdin-related sequences (CRS) antimicrobial peptides is constitutive and does not depend upon the presence of luminal bacteria as it has been found in germ-free mice. In fact, production of cryptdins and CRS1C is increased only modestly in conventional mice challenged with *S. enterica* or *Listeria monocytogenes*. In contrast, CRS4C and bactericidal lectin Reg3 γ are also produced constitutively by Paneth cells, but their secretion increases significantly following challenge with a pathogen [21,89,156]. Reg3 γ is capable of killing Gram positive bacteria by binding to their membrane peptidoglycans and disrupting the bacterial cell wall [21]. In addition to Paneth cells, goblet cells secrete cysteine protease cathepsin K (Ctsk) [144,184]. Cathepsin K contributes to maintaining the normal composition of intestinal microflora as Ctsk^{-/-} mice exhibit dysbiosis [184]. Although it has been demonstrated that other members of the cathepsin proteinase family are capable of lysing bacterial outer membranes [197], the mechanisms responsible for cathepsin K-mediated dysbiosis remain to be defined.

Another AMP produced by intestinal epithelial cells and inflammatory polymorphonuclear leukocytes (PMNs) is Lipocalin 2 (Lcn-2) [93]. This protein binds to the bacterial catecholate-type iron-chelating siderophores thereby preventing the acquisition of iron by bacterial cells, thus limiting bacterial growth [48,56]. Lcn-2 as well as heparin/heparin sulfate interacting protein (HIP/RPL29) expressed on the surface of mouse epithelial cells in the small intestine, are identical to those found in the mouse airway epithelium. These observations suggest that these proteins are part of the innate antibacterial defense of the epithelial surface in mammals [130,215]. Epithelial cell-derived AMPs are quite effective in limiting interactions between luminal bacteria and the epithelium; however, certain strains of bacteria have developed mechanisms whereby they may circumvent some of these antimicrobial properties. For instance, resistance to killing by host AMPs towards *Salmonella typhimurium* results from modifications of surface lipopolysaccharides (LPS) thereby reducing the efficacy of AMPs to bind to bacteria. In addition, *S. typhimurium* may secrete the iron-chelating molecule (salmochelin) produced by glycosylation of another siderophore, enterobactin. Salmochelin is no longer bound by Lcn-2 and it is therefore, capable of supplying bacteria with iron [60,158].

Intracellular pattern recognition receptors (PRR) and the nucleotide-binding oligomerization domain receptor (NOD) proteins NOD1 and NOD2 are important regulators of mammalian innate immune responses which are expressed in Paneth cells of the intestinal epithelium as well as in many immune cell types [14,20]. Upon recognition of specific peptidoglycans (PGN) on the bacterial cell surface, NOD1 and NOD2 activate innate immunity in an NF- κ B dependent manner [74]. In mice, it was shown that the lack of NOD2 expression causes intestinal dysbiosis [153]. Of interest,

the human intracellular pathogen *L. monocytogenes* avoids recognition by NOD proteins due to the N-deacetylation of its surface peptidoglycan, providing protection from the host lysozyme and allowing it to replicate within host macrophages [16]. Zebrafish orthologs of both mammalian *Nod1* and *Nod2* genes have been identified and are highly homologous to their mammalian counterparts. Zebrafish *Nod2* gene splicing is shown to be similar to human *Nod2* [24,101,147]. The ability to control systemic infection is markedly reduced in *NOD1*^{-/-} as well as *NOD2*^{-/-} zebrafish larvae infected with *S. enterica*. Interestingly, the expression of intestinal *duox*, a gene that encodes for an enzyme that produces H₂O₂, is decreased in *NOD1*^{-/-} larvae, but not in *NOD2*^{-/-} larvae following challenge with *S. enterica*. This suggests that, unlike in mammals, reactive oxygen species (ROS) production by DUOX in zebrafish is regulated by NOD1 and not by NOD2 [104,147]. Consistent with this hypothesis, increased bacterial load is observed in *NOD1*^{-/-}, but not in *NOD2*^{-/-} larvae [147]. In addition to DUOX, other AMPs have been identified in the teleost gut. For instance, Oehlers et al. reported expression of defensin β -like (*dfnb*) genes which are closely related to mammalian β -defensin genes, as well as expression of peptidoglycan recognition proteins (*pglyrp*) which exert their bactericidal properties against Gram positive bacteria [147]. Another group of investigators observed increased expression of cathepsin-like protein genes *ctsl1a* and *ctsl1b* as well as c-type lectin genes in the intestines of zebrafish infected by *Mycobacterium marinum* [203]. Brush border-associated alkaline phosphatase (*lap*) activity localized on zebrafish epithelial cells is also thought to be important for limiting microbe adhesion. Bacterial LPS from mucosa-associated bacteria is thought to induce the expression of Lap that dephosphorylates microbial LPS. Lap also downregulates myeloid differentiation primary response protein (MyD88)-dependent pro-inflammatory signaling in the intestine thereby preventing intestinal inflammation [7]. These data are consistent with the observation that MyD88^{-/-} larvae display reduced survival as well as compromised responses to bacterial flagellin and LPS following challenge with *Edwardsiella tarda* and *S. typhimurium* [204].

A third line of defense by which vertebrates limit contact of luminal bacteria with their gut epithelium is by the synthesis and secretion of IgA. In mammals, approximately 70% of the total body production of IgA is induced by the intestinal microbiota [112,114]. IgA class switching by mucosal B cells is maintained by retinoic acid produced constitutively by resident dendritic cells (DC) as well as by transforming growth factor- β (TGF- β) and other compounds provided by the intestinal microenvironment [113]. Numerous CD11c⁺ DCs are located in the Peyer's patches and lamina propria of the small bowel. These professional antigen presenting cells continuously sample their immediate surroundings for bacteria and bacterial antigens. If present, DCs will phagocytize whole bacteria or antigens and migrate to the mesenteric lymph nodes (MLNs) where they present microbial peptides to naïve B and T cells. Since antigen- or bacteria-loaded DCs are incapable of migrating beyond the gut draining MLNs and into the circulation, immune responses induced by their interactions with MLN-associated B and/or T cells are restricted to the gut [43,114,142,164]. Following DC-mediated activation, B cells transform into plasma cells, leave the MLNs and enter the systemic circulation. These effector cells then home back to the intestinal lamina propria where they produce bacterial-specific immunoglobulin A (IgA) [68,83,138]. This bacterial specific immunoglobulin is then transported from the intestinal interstitium through

1
2
3
4 epithelial cells via a specific pIgR receptor (see above) and into the gut lumen. Once
5 IgA is deposited onto the luminal surface of the epithelium, it may bind to bacteria in
6 close proximity to the epithelium, thereby preventing invasion of the microorganisms
7 into the gut tissue. In addition, recent studies suggest that IgA coating of luminal
8 bacteria facilitates their uptake by the M cells overlying gut-associated lymphoid tissue
9 (e.g. MLNs, isolated lymphoid follicles), thereby limiting intestinal immune responses to
10 the gut [152,185]. To date, IgA expression has not been detected in fish [22,167] and it
11 is not clear if any particular immunoglobulin class in zebrafish may be considered a
12 functional equivalent of mammalian IgA in mucosal immune responses. The *pIgR* gene
13 expression in zebrafish gut has been confirmed in a recent study and unlike in
14 mammals, zebrafish pIgR is composed of only two domains [98]. It is noteworthy that in
15 another teleost, *Takifugu rubripes* (fugu), *pIgR* is capable of binding IgM in the skin
16 mucus [61]. In another study, the relatively primitive immunoglobulin IgT, also known as
17 IgZ, is shown to function as a mucosal antibody and to be protective against intestinal
18 parasites in rainbow trout [221].

19
20 The multiple lines of defense that mammals and teleosts have developed to
21 protect against invasion of pathogenic and/or commensal bacteria are quite effective.
22 Occasional breaches in the epithelium may occur, allowing microorganisms to gain
23 access to the intestinal lamina propria. When this occurs, vertebrates mobilize their
24 fourth line of defense: the innate and adaptive immunity. The vertebrate intestine is in
25 actuality, the largest lymphoid tissue in the body which contains substantial numbers of
26 dendritic cells, phagocytic leukocytes and lymphocytes [179]. Microbes which enter the
27 gut lamina propria are rapidly phagocytized and killed by interstitial macrophages [186].
28 MyD88 signaling in these phagocytes is selectively downregulated insuring that
29 intestinal macrophages produce relatively small amounts of pro-inflammatory cytokines
30 and mediators while possessing potent bactericidal activity. This allows for the removal
31 of unwanted microbes without fully activating an inflammatory response and consequent
32 tissue injury [188,189]. These specific macrophages (called M2 macrophages) are
33 crucial for limiting bystander tissue injury produced by innate immune responses.
34 Intestinal M2 macrophages also contribute greatly to the repair of intestinal damage via
35 their ability to induce the proliferation of epithelial cells to repopulate the injured
36 epithelium [181]. The role of intestinal macrophages in teleosts has not been described
37 in as much detail as their mammalian counterparts. However, their importance was
38 demonstrated in zebrafish following intestinal pathogen *S. flexneri* infection. In
39 mammals, it was shown that invading bacteria which penetrate the intestinal epithelium
40 are phagocytized by indigenous macrophages and instead of being killed, ingested
41 bacteria leave the phagosome causing macrophage cell pyroptosis [2]. In zebrafish, this
42 leads to a dramatic decrease in macrophage numbers resulting in bacteremia and
43 eventually death of the larvae [137]. This observation is especially valuable because it
44 shows that zebrafish can be a relevant model for studying the pathogenicity of
45 microorganisms such as *S. flexneri* that are not natural fish pathogens.

46
47 Another group of heterogeneous innate immune cells that reside within the gut
48 and provide protection against invading microorganisms, as well as regulate adaptive
49 immunity and wound healing are called innate lymphoid cells (ILCs). ILCs arise from
50 hematolymphoid progenitor cells and may be categorized as cytotoxic ILCs which are
51 represented by natural killer (NK) cells and helper-like ILCs that include ILC1, ILC2 and
52
53
54
55
56
57
58
59
60
61
62
63
64
65

ILC3 [39]. NK cells and ILC1 produce large amounts of IFN- γ that is used to protect mice against infection by certain bacteria such as *L. monocytogenes* [165]. ILC2 cells may also protect mice from certain helminths such as *Trichinella spiralis* via their production of the Th2 cytokine IL-13 [126]. What was considered a subset of NK cells (i.e. NK-22 cells) was shown to protect the host against bacterial invasion as well as maintain epithelial barrier integrity. These IL-22 producing ILCs, which are now considered ILC3, produce little or no IFN- γ and express the retinoic-acid-receptor-related orphan receptor- γ t (ROR γ t) transcription factor [50,107,174,177]. It has been demonstrated that ILC3-derived IL-22 attenuates acute and chronic intestinal inflammation induced in lymphopenic mice (*Rag*^{-/-} mice) by *Citrobacter rodentium* and by adoptive transfer of naïve T cells, respectively [177,220]. Another important function of ILCs is anatomical containment of the intestinal microbiota [39,65,191]. Recent studies have demonstrated that immuno-depletion of ILCs resulted in the systemic dissemination of intestinal bacteria that was accompanied by multi-organ inflammation [191]. The loss of containment appeared to be due to the loss of ILC-derived IL-22 as the administration of IL-22 to ILC-depleted mice prevents the dissemination of commensal bacteria [191]. In follow up studies, Hepworth et. al., showed that selective depletion of MHC ROR γ t⁺ ILCs expressing major histocompatibility complex II (MHC II) resulted in dysregulated commensal bacteria-dependent CD4⁺ T cell responses that induced spontaneous and systemic dissemination of commensal bacteria resulting in multi-organ inflammation [65]. Taken together, these data suggest that intestinal homeostasis is mediated by the MHC II-dependent interaction between ILCs and CD4⁺ T cells. NK cells have currently not been described in zebrafish. It has been suggested that the recently described novel immune-type receptors (NITR) expressing cells in zebrafish and other teleosts may be functionally-equivalent to mammalian NK cells [78,218].

The adaptive immune cells (i.e. lymphocytes) represent another level of defense that synergizes with innate immune cells to maintain homeostasis, as well as protect the host from invasion of pathogenic microbes. One such group of lymphocytes that reside in large numbers within the epithelial monolayer are the intraepithelial lymphocytes (IELs). Natural IELs are either CD8 $\alpha\alpha$ ⁺ or CD8 $\alpha\alpha$ ⁻ and express TCR $\gamma\delta$ or TCR $\alpha\beta$ [27]. TCR $\gamma\delta$ IELs constitute approximately 60% of the total IELs of the small bowel and are generally thought to maintain epithelial integrity and limit immune activation [27]. Along with intestinal macrophages, TCR $\gamma\delta$ IELs are capable of producing keratinocyte growth factor (KGF) that mediates intestinal wound healing [26]. It has been shown recently that the ability of TCR $\gamma\delta$ -derived KGF to repair acute inflammatory injury in the gut is impaired in mice that lack an important ligand (semaphorin; CD100) for TCR $\gamma\delta$ activation [127]. Epithelial cells from CD100-deficient (CD100^{-/-}) or KGF^{-/-} mice exhibit significantly decreased proliferative rates in mouse models of experimental colitis. Due to the expression of the NKG2D NK receptor, TCR $\gamma\delta$ IELs are able to recognize the MHC I-like surface markers MICA and MICB expressed widely in the intestines of humans with IBD. NKG2D/MIC interaction is essential for cytotoxic killing of the enterocytes activated by allogeneic ligands [59,72]. TCR $\gamma\delta$ IELs stimulated by enterocytes may also respond to bacterial challenge by producing the AMPs Reg3 β and Reg3 γ [75]. In response to bacterial challenge, IELs

1
2
3
4 migrate to enterocytes in contact with the pathogen, thus providing the host with
5 immediate and essential protection against invading pathogen [41].

6
7 If intestinal bacteria evade the multiple layers of defense described above, they
8 will eventually be eliminated by the adaptive immune response called cell mediated
9 immunity. Whole bacteria and/or their antigens will be endocytosed by DCs within the
10 LP. Antigen-loaded DCs will then travel from the LP to the MLNs via the efferent
11 lymphatics. During this process, DCs will process and present the bacterial antigens in
12 the context of their MHC II. Upon arrival to the MLNs, naïve CD4⁺ T cells will bind to the
13 gut derived DCs via their TCR, whereupon the T cells become primed/activated and
14 polarized and expand to produce larger numbers of antigen-specific Th1 and/or Th17
15 effector cells. It is during this time that T cells become “imprinted” via the increased
16 expression of surface adhesion molecules such as CCR9, LFA-1, PSGL-1 and VLA-4.
17 Once the effector cells have departed the MLNs and enter the systemic circulation,
18 these imprinted homing proteins will direct migration of the T cells to the intestine where
19 the levels of bacteria and antigens are the greatest [94]. Following extravasation into the
20 gut LP, effector T cells will engage DCs as well as other antigen presenting cells (e.g.
21 macrophages, B cells) that have also processed and presented the same bacterial
22 antigens whereby the effector T cells become rapidly and fully activated to produce
23 large amounts of IFN- γ , IL-2, TNF- α and IL-17. Some of these cytokines will then
24 activate intestinal macrophages to “help” in their phagocytosis and killing of bacteria.
25 These inflammatory cytokines will also enhance the expression of endothelial cell
26 adhesion molecules (e.g. E-selectin, ICAM-1, VCAM-1) thereby promoting the infiltration
27 of additional phagocytic/myeloid leukocytes (e.g. PMNs, monocytes). Lugo-Villarino et
28 al. have described a zebrafish myeloid cell that strongly resembles mammalian DCs
29 morphologically and functionally and have MHC II expression [109]. Because innate and
30 adaptive immune responses produce a number of cytotoxic species such as reactive
31 oxygen and nitrogen metabolites, as well as secrete and activate different hydrolytic
32 enzymes (e.g. metalloproteinases), the host must have ways to limit inflammatory tissue
33 injury during these responses. This is accomplished by the action of thymic-derived and
34 peripheral induced regulatory Tregs [69,79,116,182]. In mice, the majority of Tregs
35 express the Foxp3 transcription factor and CD25. Thymic-derived Tregs (tTregs)
36 acquire expression of Foxp3 during their development in the thymus whereas induced
37 Tregs (iTregs) are produced from conventional CD4⁺ T cells following their interaction
38 with antigen-loaded DCs in lymphoid and nonlymphoid tissue [13,71]. Both populations
39 of Tregs utilize IL-10 and/or TGF- β to regulate innate and adaptive immune responses
40 [148].

41
42 A list of cloned genes for teleost T cell-associated peptides analogous to those
43 expressed in mammals includes α , β , γ , and δ TCR subunits as well as CD3, CD4,
44 CD8, CD28 and recombinae activated gene-1 (*Rag-1*) [9,17,57,196]. There are very
45 few studies devoted to intestinal T cell function in zebrafish. The genes for zebrafish
46 *Foxp3*, *Stat6*, and *T-bet* transcription factors have been cloned. *Foxp3* and *T-bet*
47 zebrafish genes are identical to their human homologues, while the *Stat6* gene has
48 some minor differences [132]. A gene for zebrafish IL-23 α , an essential component of
49 IL-23, an interleukin required for Th17 cell differentiation in mammals, has been cloned
50 recently as well [67]. Taken together, these data suggest that zebrafish may possess
51 Th1, Th2, Th17 and Treg cells described in mammals. Mouse T cells, transduced with
52
53
54
55
56
57
58
59
60
61
62
63
64
65

the zebrafish *Foxp3* gene, suppress activation of other T cells in *in vitro* co-culture assay [157]. Interestingly, two alternatively spliced transcripts have been discovered for the zebrafish *Foxp3* gene [132]. According to histologic staining data in rainbow trout, CD8⁺ cytotoxic T cells can make up more than half of the T cell population in the teleost's gut [196]. In sea bass, proliferation of T cells by allogeneic stimulation was reduced significantly by addition of cyclosporine A. It suggests that T cell proliferation in teleosts may be controlled by mechanisms similar to those reported for mammals [128].

4. Loss of Tolerance to the Microbiota Induces Intestinal Inflammation

The fact that vertebrates remain healthy despite the continuous presence of enormous numbers of potentially harmful microorganisms, attest to the remarkable ability of the intestinal immune system to maintain tolerance to nonpathogenic/commensal bacteria. It is becoming increasingly appreciated that the loss of tolerance to the commensal microbiota represents an important pathogenetic mechanism responsible for induction of intestinal inflammation [25,73,90,99,176,214]. Based upon their early work performed in rats and mice more than 20 years ago, Powrie and coworkers proposed that the chronic intestinal inflammation observed in patients suffering from IBD results from a dysregulated immune response to intestinal bacteria [3,79,154]. Evidence gathered over the past two decades suggests that IBD most likely arises from a complex interaction between genetic and environmental factors [73,90,99,214].

4.1 Genetic Susceptibility

To date, more than 160 different polymorphisms or susceptibility loci have been identified in patients with diagnosed IBD [25,87,90,206]. As one might expect, a substantial number of these loci common to both CD and UC are associated with innate and adaptive immunity. While the majority of the altered loci are associated with both CD and UC, genome wide associated studies (GWAS) have identified a smaller but significant number of polymorphisms that appear specific for CD. These include *NOD2*, autophagy related protein 16-like 1 (*ATG16L1*) and Immunity-Related GTPase Family M (*IRGM*) genes [87]. Furthermore, genes associated with epithelial barrier function have also been identified [87]. Because these genes express proteins that are important for recognition and processing of intracellular bacteria as well as for limiting the invasion of intestinal bacteria into the gut lamina propria, one could envision a scenario whereby CD may arise from unrelenting bacterial infections [87]. In addition to defects in innate immunity, GWAS have reported several polymorphisms in genes that are crucial for the induction and regulation of adaptive immune responses such IL-17 and IL-23 signaling and IL-10/IL-R interactions [87]. UC-specific susceptibility loci have also been described for genes responsible for HLA class II-mediated antigen presentation (e.g. *HLA-DQA1*), inflammatory mediator generation (e.g. *TNFRSF14*, *TMFRSF9*, *IL1R2*, *IL8Ra*, *IL7R*) and epithelial barrier function (e.g. *HNF4A*, *CHD1*, *LAMB1* genes) [87,92,206].

Much of our understanding of the immuno-pathogenesis of chronic gut inflammation has come from studies using mouse models of IBD [95,163,200]. Prior to the early 1990s, animal models of IBD required the oral or rectal administration of erosive chemicals to produce colonic mucosal damage that was followed by an acute self-limiting inflammatory response [95]. However, the publication of 4 paradigm-

changing studies in 1993 altered dramatically the future of experimental IBD by demonstrating that mice rendered genetically-deficient in certain genes involved in immune regulation developed spontaneous and unrelenting colitis [100,135,154,173]. Since the publication of these ground-breaking studies, numerous other, genetically-engineered mouse models of chronic intestinal inflammation have been generated that continue to provide new and important information related to the immuno-pathogenesis of experimental IBD [85,95,163]. Although none of the mouse models completely recapitulate the clinical and immuno-histopathological features of human disease, data obtained from several studies using chronic mouse models have revealed two important concepts that have served to direct basic and clinical research over the past two decades [95,163]. One basic concept that has come from these studies is that genetics play an important role in the pathogenesis of chronic inflammation. Indeed, numerous studies have shown that chronic inflammation develops in mice that possess one or more defects in genes that are involved in certain pathways related to innate and/or adaptive immune responses such as the *T-bet*^{-/-} x *Rag-2*^{-/-} ulcerative colitis (TRUC) [95,163,200].

Another important concept that has come from these mouse studies is that the “environment” (i.e. the intestinal microbiota) is required for induction and perpetuation of chronic gut inflammation in genetically-susceptible mice. Mice that are depleted of their microbiota using antibiotic administration or are delivered by caesarian section and raised under germ-free conditions develop little or no colitis [25,90,96,176]. In addition to mice, zebrafish are also being used as models for investigating the immunopathological mechanisms involved in intestinal inflammation [216]. These teleost models employ the use of chemical haptens [i.e. TNBS, oxazolone or irritants (dextran sodium sulfate (DSS))] to induce acute, self-limiting intestinal inflammation in larvae or adult fish [216]. Although not chronic in nature, these models have revealed several similarities to mouse-based models with respect to inflammation gene expression, leukocyte infiltration, intestinal injury and the requirement for intestinal bacteria [19,63,64,216]. Of note, some investigators have demonstrated that the knock down or deletion of genes that have been shown to be dysfunctional in human IBD or absent in mice that develop IBD, also increase susceptibility of zebrafish to bacterial infection [216].

4.2 Environment: Intestinal Bacteria Drive Chronic Gut Inflammation

There is no question that genetics play an important role in the pathogenesis of IBD. However, genetics alone cannot fully account for the dramatic increase in IBD in modernized societies over the past 50 years. For example, concordance rates for IBD in identical twins is actually quite low with estimates of 30-35% and 10-15% for CD and UC, respectively [10]. In addition, it has been well-documented that countries/societies that have adopted a “Modernized” lifestyle have shown sharp increases in the incidence and prevalence of IBD over the past five decades [10,32,92,134,206]. Taken together, these studies suggest that alterations in intestinal microbiota produced by environmental factors may be responsible for the increased incidence in IBD throughout the world. Multiple studies have demonstrated that increased use (and abuse) of antibiotics, better environmental sanitation, increased personal hygiene, and alterations in diet and lifestyle dramatically alter the composition of intestinal microbiota

[10,32,92,134,206]. Moreover, the rapid appearance of IBD in rural-based societies where these chronic diseases were once rare, have increased dramatically over the past 50 years following transition to more modernized communities. Taken together, these genetic and environmental observations support the hypothesis that environmental factors may play an important role in the induction of disease in genetically-susceptible individuals [10,118,134]. This is true not only for human disease but is also observed in mouse and teleost models of intestinal inflammation. As pointed out previously, many of the mouse models of chronic gut inflammation develop little or no disease in the absence of intestinal bacteria. In addition, changes in microbiota may alter dramatically the onset and/or severity of disease in these mice [95,96,163,200].

So, what exactly is the evidence that intestinal bacteria are an important pathogenetic factor that drives gut inflammation in genetically susceptible individuals? In fact, there is really only one study in humans that directly implicates intestinal bacteria in inducing IBD. Studies by Rutgeerts and coworkers showed that when the fecal stream of a segment of the small bowel that has been surgically resected (due to advanced CD) to form a neoterminal ileum was diverted, intestinal inflammation failed to develop [172]; however, when the fecal stream was restored inflammation rapidly appeared, suggesting a role for intestinal microbiota [34,172]. In addition to these direct studies, a number of indirect or association studies have been published demonstrating greater numbers of mucosa-, epithelia- and lamina propria-associated bacteria in histological samples obtained from inflamed vs. healthy intestine [25,25,118,119,122]. As mentioned previously, GWAS have revealed polymorphisms (mutations) in genes that are responsible for recognition and intracellular processing (and killing) of bacteria (i.e. *NOD2*, *ATG16L1* and *IRGM*) which are strongly associated with patients with CD [87]. Taken together, these data are consistent with the hypothesis that in addition to polymorphisms in genes associated with the adaptive immune system, defects in innate immune responses to intestinal bacteria may represent an important immunopathogenic factor that induces and perpetuates chronic intestinal inflammation [25,92,206]. The beneficial effects of certain antibiotics administered to patients with distal bowel inflammation is consistent with a role for the microbiota in disease pathogenesis [45].

Another important piece of indirect evidence implicating intestinal microbiota in the pathogenesis of human IBD is the observation that gut inflammation appears to always be accompanied by dramatic alterations in the luminal and mucosa-associated composition of intestinal bacteria, a situation called dysbiosis [176,192]. Numerous studies have reported marked dysbiosis in luminal (i.e. fecal) samples collected from humans with active IBD [54,99]. The large majority of these studies have used luminal/fecal samples and have consistently shown a decrease in bacterial diversity and abundance of bacteria within the Firmicutes and Bacteroidetes, whereas the abundance of certain Proteobacteria such as the Enterobacteriaceae (*E. coli*, AIEC) are increased [25,49,118,119,151,162,176]. However, a more recent study using large numbers of newly diagnosed, treatment-naïve patients with IBD, reports that from the trillions of possible bacteria that reside within the small and large bowel, alterations in abundance of only a select few groups of mucosa-associated bacteria were strongly correlated with presence and quality of disease [54]. This same study also emphasized that alterations observed in luminal/fecal microbial communities did not appear to correlate with disease status. These exciting studies have, for the first time, identified specific communities of

1
2
3
4 mucosa-associated bacteria that may be very important in the induction and
5 progression of chronic intestinal inflammation in genetically-susceptible individuals.
6 Specifically, Gevers and coworkers observed increased abundance of certain
7 pathobionts including Enterobacteriaceae, Pasteurellaceae, Veillonellaceae and
8 Fusobacteriaceae as well as decreased abundance of “protective” Erysipelotrichales,
9 Bacteroidales and Clostridiales [54]. Pathobionts are constituents of the healthy
10 microbiota and are not considered classical pathogens; however these bacteria possess
11 the potential to induce gut inflammation following disruption of the healthy microbiota
12 [171].

13
14
15 Dysbiosis is also commonly observed in several mouse models of IBD [95,96].
16 Two more recent mouse models have extensively characterized this dysbiosis with the
17 objective of defining the specific populations of pathobionts responsible for induction of
18 disease. One model is the TRUC mouse model. This genetically-engineered mouse
19 develops spontaneous, chronic and communicable colitis that is driven by the
20 interaction between innate immune cells and the microbiota [53]. The fact that colitis is
21 communicable and will develop in wild type mice when housed with TRUC mice
22 suggests that there is an outgrowth of pathogenic bacteria in these mice [53].
23 Investigators have observed an overabundance of *Klebsiella pneumoniae* and *Proteus*
24 *mirabilis* that correlated well with disease [52]. These two microbes are known to be
25 increased in human IBD [52,53]. Another novel mouse model of IBD that requires the
26 presence of intestinal bacteria and exhibits dysbiosis was created by Kang et. al. [88].
27 These investigators bred dominant negative TGF β RII (dnTGF β RII) mice with IL-10R2^{-/-}
28 mice to generate dnTGF β RII X IL-10R2^{-/-} offspring which are referred to as dnKO mice.
29 These offspring have defective TGF β signaling in T cells and defects in IL-10R signaling
30 in all tissues [88]. These dnKO mice develop an accelerated and unrelenting colitis that
31 is abrogated by administration of broad spectrum antibiotics [88]. This same laboratory
32 has also demonstrated that an isolate of *Bacteroides*, but not *Enterobacteriaceae*
33 induces robust disease in dnKO but not in controls [15,66]. Taken together, these
34 studies clearly demonstrate the need to assess the colitogenic potential rather than
35 relying solely on 16S rRNA determinations. Despite the potentially important role that
36 dysbiosis may play in the pathogenesis of IBD, it remains unclear whether dysbiosis is a
37 cause or consequence of chronic gut inflammation. There are a few reports showing
38 that dysbiosis may occur in healthy relatives of patients with IBD, suggesting that
39 microbial alterations may precede disease, but little follow up of these family members
40 has been documented [86]. In fact, it has been well-documented that products of the
41 inflammatory reaction are effective at promoting dysbiosis [111]. Defining the role of
42 dysbiosis in IBD may have to await more direct longitudinal studies that can only be
43 accomplished in well-controlled mouse models of IBD. It should be noted that the
44 intestinal microbiota has also been shown to be important for full expression of
45 chemically-induced intestinal inflammation in zebrafish [19,63,64,216].

4.3 Intestinal Microbiota Transplant: A novel therapeutic strategy for treating IBD

46
47
48 Great advances have been made over the past 30 years in understanding the
49 immuno-pathological mechanisms responsible for the induction and perpetuation of
50 IBD. Yet, only a handful of pharmacologic and biologic agents are available to treat
51 these debilitating inflammatory disorders. Furthermore, many of the current

1
2
3
4 immunosuppressive small molecules available for patients may be toxic and the new-
5 generation biologics can be expensive and require infusion in a physician's office. Thus,
6 it is critical that additional, nontoxic and inexpensive therapies be developed to treat
7 patients with IBD. Given the fact that there is now considerable experimental and
8 clinical evidence demonstrating that the intestinal microbiota may act as a "trigger" to
9 induce and perpetuate chronic gut inflammation in genetically-susceptible individuals,
10 investigators have undertaken different avenues of research in an attempt to restore the
11 dysbiotic gut microbiota that develops in patients with active IBD to a more typical,
12 highly diverse community of microorganisms. A variety of different approaches have
13 been used to manipulate the intestinal microbiota in IBD patients including the use of
14 antibiotics, probiotics, and prebiotics. Manipulating the dysbiotic microbiota to decrease
15 disease-producing pathobionts, while enhancing the numbers and metabolic activity of
16 beneficial bacterial communities, has tremendous potential for therapeutic benefit. The
17 therapeutic efficacy of antibiotic, probiotic and/or prebiotic administration in patients with
18 IBD has not been proven in placebo-controlled, double blind, multicenter clinical studies.
19 However, there are encouraging data suggesting that oral administration of ciprofloxacin
20 and/or metronidazole may be effective in attenuating distal bowel inflammation in
21 patients with CD [105,155,176,207]. Currently, antibiotic therapy is primarily used to
22 treat complications such as fistulas and ulcers in IBD patients.

23
24
25
26
27
28 A great deal of interest has been generated following the publication of a recent
29 clinical study that demonstrated that transplantation (i.e. colonization) of healthy fecal
30 microbiota into patients with recurrent *Clostridium difficile* colitis essentially cured this
31 recurrent and intractable infection [205]. Van Nood et. al., showed that 94% of the
32 patients that received microbiota transplantation (FMT) had complete resolution of
33 disease whereas only 31% of patients receiving current therapy (e.g. vancomycin)
34 showed significant improvement [205]. These studies produced a great deal of
35 excitement about the possible use of FMT in the treatment of IBD. Although a few open
36 label case/cohort studies have reported tantalizing evidence suggesting a beneficial
37 effect of FMT in the treatment of IBD, by and large, these studies are small, statistically
38 underpowered and/or uncontrolled investigations. Two recent well-controlled clinical
39 studies have been published that assessed the therapeutic efficacy of FMT in patients
40 with UC. In one study, Moayyedi and coworkers reported, in a randomized, double
41 blinded, placebo controlled study that a significantly greater percentage of patients
42 receiving weekly FMT for 6 weeks achieved remission than those patients receiving a
43 placebo (i.e. water; 24% vs. 5%) [133]. In the other study, Rossen et. al., treated one
44 group of patients with active UC with healthy FMT or autologous FMT (infusion of
45 patients own feces to serve as a placebo). These investigators found no significant
46 difference in clinical and endoscopic remission between the two groups [170]. The
47 reasons for the different outcomes in the two studies are not entirely clear at the present
48 time. The two studies did, in fact, contain several major differences including location
49 and frequency of the FMT infusion, concurrent use of anti-TNF therapy in one study, but
50 not the other and possible donor microbial composition for efficacy [58,170].
51 Nevertheless, both of these studies reconfirm previous observations that FMT is well-
52 tolerated. One potential caveat that has not been adequately addressed is whether the
53 dysbiosis observed in patients with IBD is a cause or consequence of gut inflammation.
54 If in fact dysbiosis is initially created by subclinical inflammation in genetically

susceptible individuals leading to the expansion of disease-producing pathobionts such as adherent/invasive *Enterobacteriaceae*, the use of FMT may not prove as effective as it would be if dysbiosis were the primary trigger of disease [212,213].

5. Conclusions

The vertebrate intestine is home to the vast majority of bacteria present on and within the body. The coexistence of mammals and teleosts with their gut microbiota is a continuously evolving process that provides numerous advantages to both host and bacteria. The intestinal microbiota which is now considered a virtual organ provides the host with the immunologic stimuli, nutrients and vitamins required for developing and maintaining health of the host. In turn, the host provides a physiological environment that is conducive for the steady-state bacterial colonization of the gut. The fact that mammal and teleost homeostasis is maintained in the presence of such large numbers of potentially dangerous microorganisms is testament to the remarkable ability of the intestinal immune system in these land and aquatic animals to maintain tolerance to commensal bacteria while mounting effective immune responses to pathogenic microbes. The inability of the intestinal immune system to maintain tolerance to the intestinal microbiota is thought to be a major immuno-pathogenic mechanism responsible for the induction of IBD in humans. Indeed, there is an accumulating literature suggesting that Crohn's disease and/or ulcerative colitis results from a dysregulation of immune responses toward intestinal bacteria in genetically-susceptible individuals.

Conflict of interest

The authors declare that there is no conflict of interest.

Acknowledgements

Some of the work reported in this manuscript was supported by grants from the DOD (W81XWH-11-1-0666; MBG) and the NIH (R01-DK091269; MBG)

Reference List

- [1] L. Albenberg, T. V. Esipova, C. P. Judge, K. Bittinger, J. Chen, A. Laughlin, S. Grunberg, R. N. Baldassano, J. D. Lewis, H. Li, S. R. Thom, F. D. Bushman, S. A. Vinogradov, and G. D. Wu, Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota, *Gastroenterology*, 147 (2014) 1055-1063.
- [2] H. Ashida, M. Ogawa, M. Kim, S. Suzuki, T. Sanada, C. Punginelli, H. Mimuro, and C. Sasakawa, Shigella deploy multiple countermeasures against host innate immune responses, *Curr. Opin. Microbiol.*, 14 (2011) 16-23.

- [3] C. Asseman, S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie, An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation, *J. Exp. Med.*, 190 (1999) 995-1004.
- [4] K. Atarashi, T. Tanoue, T. Shima, A. Imaoka, T. Kuwahara, Y. Momose, G. Cheng, S. Yamasaki, T. Saito, Y. Ohba, T. Taniguchi, K. Takeda, S. Hori, I. I. Ivanov, Y. Umesaki, K. Itoh, and K. Honda, Induction of colonic regulatory T cells by indigenous *Clostridium* species, *Science*, 331 (2011) 337-341.
- [5] S. J. Aujla, P. J. Dubin, and J. K. Kolls, Th17 cells and mucosal host defense, *Semin. Immunol.*, 19 (2007) 377-382.
- [6] E. Avershina, O. Storro, T. Oien, R. Johnsen, P. Pope, and K. Rudi, Major faecal microbiota shifts in composition and diversity with age in a geographically restricted cohort of mothers and their children, *FEMS Microbiol. Ecol.*, 87 (2014) 280-290.
- [7] J. M. Bates, J. Akerlund, E. Mittge, and K. Guillemin, Intestinal alkaline phosphatase detoxifies lipopolysaccharide and prevents inflammation in zebrafish in response to the gut microbiota, *Cell Host. Microbe*, 2 (2007) 371-382.
- [8] J. M. Bates, E. Mittge, J. Kuhlman, K. N. Baden, S. E. Cheesman, and K. Guillemin, Distinct signals from the microbiota promote different aspects of zebrafish gut differentiation, *Dev. Biol.*, 297 (2006) 374-386.
- [9] D. Bernard, A. Six, L. Rigottier-Gois, S. Messiaen, S. Chilmonczyk, E. Quillet, P. Boudinot, and A. Benmansour, Phenotypic and functional similarity of gut intraepithelial and systemic T cells in a teleost fish, *J. Immunol.*, 176 (2006) 3942-3949.
- [10] C. N. Bernstein and F. Shanahan, Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases, *Gut*, 57 (2008) 1185-1191.
- [11] C. L. Bevins, Innate immune functions of alpha-defensins in the small intestine, *Dig. Dis.*, 31 (2013) 299-304.
- [12] E. Bianconi, A. Piovesan, F. Facchin, A. Beraudi, R. Casadei, F. Frabetti, L. Vitale, M. C. Pelleri, S. Tassani, F. Piva, S. Perez-Amodio, P. Strippoli, and S. Canaider, An estimation of the number of cells in the human body, *Ann. Hum. Biol.*, 40 (2013) 463-471.
- [13] A. M. Bilate and J. J. Lafaille, Induced CD4⁺Foxp3⁺ regulatory T cells in immune tolerance, *Annu. Rev. Immunol.*, 30 (2012) 733-758.
- [14] A. Biswas, T. Petnicki-Ocwieja, and K. S. Kobayashi, Nod2: a key regulator linking microbiota to intestinal mucosal immunity, *J. Mol. Med. (Berl)*, 90 (2012) 15-24.

- [15] S. M. Bloom, V. N. Bijanki, G. M. Nava, L. Sun, N. P. Malvin, D. L. Donermeyer, W. M. Dunne, Jr., P. M. Allen, and T. S. Stappenbeck, Commensal *Bacteroides* species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease, *Cell Host. Microbe*, 9 (2011) 390-403.
- [16] I. G. Boneca, O. Dussurget, D. Cabanes, M. A. Nahori, S. Sousa, M. Lecuit, E. Psyllinakis, V. Bouriotis, J. P. Hugot, M. Giovannini, A. Coyle, J. Bertin, A. Namane, J. C. Rousselle, N. Cayet, M. C. Prevost, V. Balloy, M. Chignard, D. J. Philpott, P. Cossart, and S. E. Girardin, A critical role for peptidoglycan N-deacetylation in *Listeria* evasion from the host innate immune system, *Proc. Natl. Acad. Sci. U. S. A.*, 104 (2007) 997-1002.
- [17] I. Boschi, E. Randelli, F. Buonocore, D. Casani, C. Bernini, A. M. Fausto, and G. Scapigliati, Transcription of T cell-related genes in teleost fish, and the European sea bass (*Dicentrarchus labrax*) as a model, *Fish. Shellfish. Immunol.*, 31 (2011) 655-662.
- [18] E. M. Brown, M. Sadarangani, and B. B. Finlay, The role of the immune system in governing host-microbe interactions in the intestine, *Nat. Immunol.*, 14 (2013) 660-667.
- [19] S. Brugman, K. Y. Liu, D. Lindenbergh-Kortleve, J. N. Samsom, G. T. Furuta, S. A. Renshaw, R. Willemsen, and E. E. Nieuwenhuis, Oxazolone-induced enterocolitis in zebrafish depends on the composition of the intestinal microbiota, *Gastroenterology*, 137 (2009) 1757-1767.
- [20] R. Caruso, N. Warner, N. Inohara, and G. Nunez, NOD1 and NOD2: signaling, host defense, and inflammatory disease, *Immunity*, 41 (2014) 898-908.
- [21] H. L. Cash, C. V. Whitham, C. L. Behrendt, and L. V. Hooper, Symbiotic bacteria direct expression of an intestinal bactericidal lectin, *Science*, 313 (2006) 1126-1130.
- [22] R. Castro, L. Jouneau, H. P. Pham, O. Bouchez, V. Giudicelli, M. P. Lefranc, E. Quillet, A. Benmansour, F. Cazals, A. Six, S. Fillatreau, O. Sunyer, and P. Boudinot, Teleost fish mount complex clonal IgM and IgT responses in spleen upon systemic viral infection, *PLoS. Pathog.*, 9 (2013) e1003098.
- [23] J. P. Celli, B. S. Turner, N. H. Afdhal, S. Keates, I. Ghiran, C. P. Kelly, R. H. Ewoldt, G. H. McKinley, P. So, S. Erramilli, and R. Bansil, *Helicobacter pylori* moves through mucus by reducing mucin viscoelasticity, *Proc. Natl. Acad. Sci. U. S. A.*, 106 (2009) 14321-14326.
- [24] M. X. Chang, W. Q. Chen, and P. Nie, Structure and expression pattern of teleost caspase recruitment domain (CARD) containing proteins that are potentially involved in NF-kappaB signalling, *Dev. Comp Immunol.*, 34 (2010) 1-13.

- [25] B. Chassaing and A. Darfeuille-Michaud, The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases, *Gastroenterology*, 140 (2011) 1720-1728.
- [26] Y. Chen, K. Chou, E. Fuchs, W. L. Havran, and R. Boismenu, Protection of the intestinal mucosa by intraepithelial gamma delta T cells, *Proc. Natl. Acad. Sci. U. S. A.*, 99 (2002) 14338-14343.
- [27] H. Cheroutre, F. Lambolez, and D. Mucida, The light and dark sides of intestinal intraepithelial lymphocytes, *Nat Rev. Immunol.*, 11 (2011) 445-456.
- [28] H. Chung, S. J. Pamp, J. A. Hill, N. K. Surana, S. M. Edelman, E. B. Troy, N. C. Reading, E. J. Villablanca, S. Wang, J. R. Mora, Y. Umesaki, D. Mathis, C. Benoist, D. A. Relman, and D. L. Kasper, Gut immune maturation depends on colonization with a host-specific microbiota, *Cell*, 149 (2012) 1578-1593.
- [29] J. C. Clemente, L. K. Ursell, L. W. Parfrey, and R. Knight, The impact of the gut microbiota on human health: an integrative view, *Cell*, 148 (2012) 1258-1270.
- [30] K. D. Clements, E. R. Angert, W. L. Montgomery, and J. H. Choat, Intestinal microbiota in fishes: what's known and what's not, *Mol. Ecol.*, 23 (2014) 1891-1898.
- [31] J. L. Coombes, N. J. Robinson, K. J. Maloy, H. H. Uhlig, and F. Powrie, Regulatory T cells and intestinal homeostasis, *Immunol. Rev.*, 204 (2005) 184-194.
- [32] J. Cosnes, C. Gower-Rousseau, P. Seksik, and A. Cortot, Epidemiology and natural history of inflammatory bowel diseases, *Gastroenterology*, 140 (2011) 1785-1794.
- [33] A. D'costa and I. T. Shepherd, Zebrafish development and genetics: introducing undergraduates to developmental biology and genetics in a large introductory laboratory class, *Zebrafish.*, 6 (2009) 169-177.
- [34] G. R. D'Haens, K. Geboes, M. Peeters, F. Baert, F. Penninckx, and P. Rutgeerts, Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum, *Gastroenterology*, 114 (1998) 262-267.
- [35] M. F. de La Cochetiere, T. Durand, P. Lepage, A. Bourreille, J. P. Galmiche, and J. Dore, Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge, *J. Clin. Microbiol.*, 43 (2005) 5588-5592.
- [36] L. Dethlefsen, P. B. Eckburg, E. M. Bik, and D. A. Relman, Assembly of the human intestinal microbiota, *Trends Ecol. Evol.*, 21 (2006) 517-523.
- [37] T. Dobzhansky, *Genetics of the evolutionary process*, Columbia University Press, 1970.

- [38] G. P. Donaldson, S. M. Lee, and S. K. Mazmanian, Gut biogeography of the bacterial microbiota, *Nat. Rev. Microbiol.*, (2015).
- [39] G. Eberl, J. P. Di Santo, and E. Vivier, The brave new world of innate lymphoid cells, *Nat Immunol.*, 16 (2015) 1-5.
- [40] P. B. Eckburg, E. M. Bik, C. N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S. R. Gill, K. E. Nelson, and D. A. Relman, Diversity of the human intestinal microbial flora, *Science*, 308 (2005) 1635-1638.
- [41] K. L. Edelblum, G. Singh, M. A. Odenwald, A. Lingaraju, B. K. El, R. McLeod, A. I. Sperling, and J. R. Turner, gammadelta Intraepithelial Lymphocyte Migration Limits Transepithelial Pathogen Invasion and Systemic Disease in Mice, *Gastroenterology*, 148 (2015) 1417-1426.
- [42] M. G. Espey, Role of oxygen gradients in shaping redox relationships between the human intestine and its microbiota, *Free Radic. Biol. Med.*, 55 (2013) 130-140.
- [43] J. Farache, I. Koren, I. Milo, I. Gurevich, K. W. Kim, E. Zigmond, G. C. Furtado, S. A. Lira, and G. Shakh, Luminal Bacteria Recruit CD103(+) Dendritic Cells into the Intestinal Epithelium to Sample Bacterial Antigens for Presentation, *Immunity*, 38 (2013) 581-595.
- [44] F. Fava and S. Danese, Intestinal microbiota in inflammatory bowel disease: friend of foe?, *World J. Gastroenterol.*, 17 (2011) 557-566.
- [45] M. Feller, K. Huwiler, A. Schoepfer, A. Shang, H. Furrer, and M. Egger, Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials, *Clin. Infect. Dis.*, 50 (2010) 473-480.
- [46] M. F. Flajnik and M. Kasahara, Origin and evolution of the adaptive immune system: genetic events and selective pressures, *Nat. Rev. Genet.*, 11 (2010) 47-59.
- [47] A. Fleming, J. Jankowski, and P. Goldsmith, In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease: a feasibility study, *Inflamm. Bowel Dis.*, 16 (2010) 1162-1172.
- [48] T. H. Flo, K. D. Smith, S. Sato, D. J. Rodriguez, M. A. Holmes, R. K. Strong, S. Akira, and A. Aderem, Lipocalin 2 mediates an innate immune response to bacterial infection by sequestering iron, *Nature*, 432 (2004) 917-921.
- [49] D. N. Frank, A. L. St Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, *Proc. Natl. Acad. Sci. U. S. A.*, 104 (2007) 13780-13785.

- [50] A. Fuchs and M. Colonna, Natural killer (NK) and NK-like cells at mucosal epithelia: Mediators of anti-microbial defense and maintenance of tissue integrity, *Eur. J. Microbiol. Immunol. (Bp)*, 1 (2011) 257-266.
- [51] J. Galindo-Villegas, D. Garcia-Moreno, O. S. de, J. Meseguer, and V. Mulero, Regulation of immunity and disease resistance by commensal microbes and chromatin modifications during zebrafish development, *Proc. Natl. Acad. Sci. U. S. A.*, 109 (2012) E2605-E2614.
- [52] W. S. Garrett, C. A. Gallini, T. Yatsunenko, M. Michaud, A. DuBois, M. L. Delaney, S. Punit, M. Karlsson, L. Bry, J. N. Glickman, J. I. Gordon, A. B. Onderdonk, and L. H. Glimcher, Enterobacteriaceae act in concert with the gut microbiota to induce spontaneous and maternally transmitted colitis, *Cell Host. Microbe*, 8 (2010) 292-300.
- [53] W. S. Garrett, G. M. Lord, S. Punit, G. Lugo-Villarino, S. K. Mazmanian, S. Ito, J. N. Glickman, and L. H. Glimcher, Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system, *Cell*, 131 (2007) 33-45.
- [54] D. Gevers, S. Kugathasan, L. A. Denson, Y. Vazquez-Baeza, T. W. Van, B. Ren, E. Schwager, D. Knights, S. J. Song, M. Yassour, X. C. Morgan, A. D. Kostic, C. Luo, A. Gonzalez, D. McDonald, Y. Haberman, T. Walters, S. Baker, J. Rosh, M. Stephens, M. Heyman, J. Markowitz, R. Baldassano, A. Griffiths, F. Sylvester, D. Mack, S. Kim, W. Crandall, J. Hyams, C. Huttenhower, R. Knight, and R. J. Xavier, The treatment-naive microbiome in new-onset Crohn's disease, *Cell Host. Microbe*, 15 (2014) 382-392.
- [55] S. R. Gill, M. Pop, R. T. Deboy, P. B. Eckburg, P. J. Turnbaugh, B. S. Samuel, J. I. Gordon, D. A. Relman, C. M. Fraser-Liggett, and K. E. Nelson, Metagenomic analysis of the human distal gut microbiome, *Science*, 312 (2006) 1355-1359.
- [56] D. H. Goetz, M. A. Holmes, N. Borregaard, M. E. Bluhm, K. N. Raymond, and R. K. Strong, The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition, *Mol. Cell*, 10 (2002) 1033-1043.
- [57] D. Gomez, J. O. Sunyer, and I. Salinas, The mucosal immune system of fish: the evolution of tolerating commensals while fighting pathogens, *Fish. Shellfish. Immunol.*, 35 (2013) 1729-1739.
- [58] A. M. Grinspan and C. R. Kelly, Fecal Microbiota Transplantation for Ulcerative Colitis: Not Just Yet, *Gastroenterology*, 149 (2015) 15-18.
- [59] V. Groh, A. Steinle, S. Bauer, and T. Spies, Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells, *Science*, 279 (1998) 1737-1740.
- [60] J. S. Gunn, S. S. Ryan, J. C. Van Velkinburgh, R. K. Ernst, and S. I. Miller, Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for

- lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of *Salmonella enterica* serovar typhimurium, *Infect. Immun.*, 68 (2000) 6139-6146.
- [61] K. Hamuro, H. Suetake, N. R. Saha, K. Kikuchi, and Y. Suzuki, A teleost polymeric Ig receptor exhibiting two Ig-like domains transports tetrameric IgM into the skin, *J. Immunol.*, 178 (2007) 5682-5689.
- [62] M. Haynes and F. Rohwer, The human virome, in: K. E. Nelson (Ed.), *Metagenomics of the Human Body*, Springer, New York, 2011, pp. 63-78.
- [63] Q. He, L. Wang, F. Wang, and Q. Li, Role of gut microbiota in a zebrafish model with chemically induced enterocolitis involving toll-like receptor signaling pathways, *Zebrafish.*, 11 (2014) 255-264.
- [64] Q. He, L. Wang, F. Wang, C. Wang, C. Tang, Q. Li, J. Li, and Q. Zhao, Microbial fingerprinting detects intestinal microbiota dysbiosis in Zebrafish models with chemically-induced enterocolitis, *BMC Microbiol.*, 13 (2013) 289.
- [65] M. R. Hepworth, L. A. Monticelli, T. C. Fung, C. G. Ziegler, S. Grunberg, R. Sinha, A. R. Mantegazza, H. L. Ma, A. Crawford, J. M. Angelosanto, E. J. Wherry, P. A. Koni, F. D. Bushman, C. O. Elson, G. Eberl, D. Artis, and G. F. Sonnenberg, Innate lymphoid cells regulate CD4⁺ T-cell responses to intestinal commensal bacteria, *Nature*, 498 (2013) 113-117.
- [66] C. A. Hickey, K. A. Kuhn, D. L. Donermeyer, N. T. Porter, C. Jin, E. A. Cameron, H. Jung, G. E. Kaiko, M. Wegorzewska, N. P. Malvin, R. W. Glowacki, G. C. Hansson, P. M. Allen, E. C. Martens, and T. S. Stappenbeck, Colitogenic *Bacteroides thetaiotaomicron* Antigens Access Host Immune Cells in a Sulfatase-Dependent Manner via Outer Membrane Vesicles, *Cell Host. Microbe*, 17 (2015) 672-680.
- [67] A. Holt, S. Mitra, A. M. van der Sar, A. Alnabulsi, C. J. Secombes, and S. Bird, Discovery of zebrafish (*Danio rerio*) interleukin-23 alpha (IL-23alpha) chain, a subunit important for the formation of IL-23, a cytokine involved in the development of Th17 cells and inflammation, *Mol. Immunol.*, 48 (2011) 981-991.
- [68] L. V. Hooper, D. R. Littman, and A. J. Macpherson, Interactions between the microbiota and the immune system, *Science*, 336 (2012) 1268-1273.
- [69] L. V. Hooper and A. J. Macpherson, Immune adaptations that maintain homeostasis with the intestinal microbiota, *Nat. Rev. Immunol.*, 10 (2010) 159-169.
- [70] L. V. Hooper, T. Midtvedt, and J. I. Gordon, How host-microbial interactions shape the nutrient environment of the mammalian intestine, *Annu. Rev. Nutr.*, 22 (2002) 283-307.

- [71] S. Hori, Lineage stability and phenotypic plasticity of Foxp3(+) regulatory T cells, *Immunol. Rev.*, 259 (2014) 159-172.
- [72] S. Hue, J. J. Mention, R. C. Monteiro, S. Zhang, C. Cellier, J. Schmitz, V. Verkarre, N. Fodil, S. Bahram, N. Cerf-Bensussan, and S. Caillat-Zucman, A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease, *Immunity.*, 21 (2004) 367-377.
- [73] C. Huttenhower, A. D. Kostic, and R. J. Xavier, Inflammatory bowel disease as a model for translating the microbiome, *Immunity.*, 40 (2014) 843-854.
- [74] N. Inohara and G. Nunez, The NOD: a signaling module that regulates apoptosis and host defense against pathogens, *Oncogene*, 20 (2001) 6473-6481.
- [75] A. S. Ismail, K. M. Severson, S. Vaishnava, C. L. Behrendt, X. Yu, J. L. Benjamin, K. A. Ruhn, B. Hou, A. L. DeFranco, F. Yarovinsky, and L. V. Hooper, Gammadelta intraepithelial lymphocytes are essential mediators of host-microbial homeostasis at the intestinal mucosal surface, *Proc. Natl. Acad. Sci. U. S. A.*, 108 (2011) 8743-8748.
- [76] I. I. Ivanov, K. Atarashi, N. Manel, E. L. Brodie, T. Shima, U. Karaoz, D. Wei, K. C. Goldfarb, C. A. Santee, S. V. Lynch, T. Tanoue, A. Imaoka, K. Itoh, K. Takeda, Y. Umesaki, K. Honda, and D. R. Littman, Induction of intestinal Th17 cells by segmented filamentous bacteria, *Cell*, 139 (2009) 485-498.
- [77] I. I. Ivanov and D. R. Littman, Modulation of immune homeostasis by commensal bacteria, *Curr. Opin. Microbiol.*, 14 (2011) 106-114.
- [78] N. Iwanami, Zebrafish as a model for understanding the evolution of the vertebrate immune system and human primary immunodeficiency, *Exp. Hematol.*, 42 (2014) 697-706.
- [79] A. Izcue, J. L. Coombes, and F. Powrie, Regulatory lymphocytes and intestinal inflammation, *Annu. Rev. Immunol.*, 27 (2009) 313-338.
- [80] I. Jevtov, T. Samuelsson, G. Yao, A. Amsterdam, and K. Ribbeck, Zebrafish as a model to study live mucus physiology, *Sci. Rep.*, 4 (2014) 6653.
- [81] E. Jimenez, M. L. Marin, R. Martin, J. M. Odriozola, M. Olivares, J. Xaus, L. Fernandez, and J. M. Rodriguez, Is meconium from healthy newborns actually sterile?, *Res. Microbiol.*, 159 (2008) 187-193.
- [82] F. E. Johansen, M. Pekna, I. N. Norderhaug, B. Haneberg, M. A. Hietala, P. Krajci, C. Betsholtz, and P. Brandtzaeg, Absence of epithelial immunoglobulin A transport, with increased mucosal leakiness, in polymeric immunoglobulin receptor/secretory component-deficient mice, *J. Exp. Med.*, 190 (1999) 915-922.

- [83] C. Johansson and B. L. Kelsall, Phenotype and function of intestinal dendritic cells, *Semin. Immunol.*, 17 (2005) 284-294.
- [84] M. E. Johansson, H. Sjovall, and G. C. Hansson, The gastrointestinal mucus system in health and disease, *Nat. Rev. Gastroenterol. Hepatol.*, (2013).
- [85] Y. L. Jones-Hall and M. B. Grisham, Immunopathological characterization of selected mouse models of inflammatory bowel disease: Comparison to human disease, *Pathophysiology.*, 21 (2014) 267-288.
- [86] M. Joossens, G. Huys, M. Cnockaert, P. De, V, K. Verbeke, P. Rutgeerts, P. Vandamme, and S. Vermeire, Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives, *Gut*, 60 (2011) 631-637.
- [87] L. Jostins, S. Ripke, R. K. Weersma, R. H. Duerr, D. P. McGovern, K. Y. Hui, J. C. Lee, L. P. Schumm, Y. Sharma, C. A. Anderson, J. Essers, M. Mitrovic, K. Ning, I. Cleynen, E. Theatre, S. L. Spain, S. Raychaudhuri, P. Goyette, Z. Wei, C. Abraham, J. P. Achkar, T. Ahmad, L. Amininejad, A. N. Ananthakrishnan, V. Andersen, J. M. Andrews, L. Baidoo, T. Balschun, P. A. Bampton, A. Bitton, G. Boucher, S. Brand, C. Buning, A. Cohain, S. Cichon, M. D'Amato, J. D. De, K. L. Devaney, M. Dubinsky, C. Edwards, D. Ellinghaus, L. R. Ferguson, D. Franchimont, K. Fransen, R. Gearry, M. Georges, C. Gieger, J. Glas, T. Haritunians, A. Hart, C. Hawkey, M. Hedl, X. Hu, T. H. Karlsen, L. Kupcinskis, S. Kugathasan, A. Latiano, D. Laukens, I. C. Lawrance, C. W. Lees, E. Louis, G. Mahy, J. Mansfield, A. R. Morgan, C. Mowat, W. Newman, O. Palmieri, C. Y. Ponsioen, U. Potocnik, N. J. Prescott, M. Regueiro, J. I. Rotter, R. K. Russell, J. D. Sanderson, M. Sans, J. Satsangi, S. Schreiber, L. A. Simms, J. Sventoraityte, S. R. Targan, K. D. Taylor, M. Tremelling, H. W. Verspaget, V. M. De, C. Wijmenga, D. C. Wilson, J. Winkelmann, R. J. Xavier, S. Zeissig, B. Zhang, C. K. Zhang, H. Zhao, M. S. Silverberg, V. Annese, H. Hakonarson, S. R. Brant, G. Radford-Smith, C. G. Mathew, J. D. Rioux, E. E. Schadt, M. J. Daly, A. Franke, M. Parkes, S. Vermeire, J. C. Barrett, and J. H. Cho, Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease, *Nature*, 491 (2012) 119-124.
- [88] S. S. Kang, S. M. Bloom, L. A. Norian, M. J. Geske, R. A. Flavell, T. S. Stappenbeck, and P. M. Allen, An antibiotic-responsive mouse model of fulminant ulcerative colitis, *PLoS. Med.*, 5 (2008) e41.
- [89] J. Karlsson, K. Putsep, H. Chu, R. J. Kays, C. L. Bevins, and M. Andersson, Regional variations in Paneth cell antimicrobial peptide expression along the mouse intestinal tract, *BMC. Immunol.*, 9 (2008) 37.
- [90] A. Kaser, S. Zeissig, and R. S. Blumberg, Inflammatory bowel disease, *Annu. Rev. Immunol.*, 28 (2010) 573-621.

- [91] F. Kawai, S. Paek, K. J. Choi, M. Prouty, M. I. Kanipes, P. Guerry, and H. J. Yeo, Crystal structure of JlpA, a surface-exposed lipoprotein adhesin of *Campylobacter jejuni*, *J. Struct. Biol.*, 177 (2012) 583-588.
- [92] B. Khor, A. Gardet, and R. J. Xavier, Genetics and pathogenesis of inflammatory bowel disease, *Nature*, 474 (2011) 307-317.
- [93] L. Kjeldsen, J. B. Cowland, and N. Borregaard, Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse, *Biochim. Biophys. Acta*, 1482 (2000) 272-283.
- [94] I. Kobozev, F. Karlsson, and M. B. Grisham, Gut-associated lymphoid tissue, T cell trafficking, and chronic intestinal inflammation, *Ann. N. Y. Acad. Sci.*, 1207 Suppl 1 (2010) E86-E93.
- [95] I. Kobozev, F. Karlsson, S. Zhang, and M. B. Grisham, Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies, *Inflamm. Bowel. Dis.*, 17 (2011) 1229-1245.
- [96] I. Kobozev, W. C. Reinoso, K. L. Furr, and M. B. Grisham, Role of the enteric microbiota in intestinal homeostasis and inflammation, *Free Radic. Biol. Med.*, 68 (2014) 122-133.
- [97] J. E. Koenig, A. Spor, N. Scalfone, A. D. Fricker, J. Stombaugh, R. Knight, L. T. Angenent, and R. E. Ley, Succession of microbial consortia in the developing infant gut microbiome, *Proc. Natl. Acad. Sci. U. S. A.*, 108 Suppl 1 (2011) 4578-4585.
- [98] A. N. Kortum, I. Rodriguez-Nunez, J. Yang, J. Shim, D. Runft, M. L. O'Driscoll, R. N. Haire, J. P. Cannon, P. M. Turner, R. T. Litman, C. H. Kim, M. N. Neely, G. W. Litman, and J. A. Yoder, Differential expression and ligand binding indicate alternative functions for zebrafish polymeric immunoglobulin receptor (pIgR) and a family of pIgR-like (PIGRL) proteins, *Immunogenetics*, 66 (2014) 267-279.
- [99] A. D. Kostic, R. J. Xavier, and D. Gevers, The microbiome in inflammatory bowel disease: current status and the future ahead, *Gastroenterology*, 146 (2014) 1489-1499.
- [100] R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller, Interleukin-10-deficient mice develop chronic enterocolitis, *Cell*, 75 (1993) 263-274.
- [101] K. J. Laing, M. K. Purcell, J. R. Winton, and J. D. Hansen, A genomic view of the NOD-like receptor family in teleost fish: identification of a novel NLR subfamily in zebrafish, *BMC. Evol. Biol.*, 8 (2008) 42.
- [102] R. E. Ley, D. A. Peterson, and J. I. Gordon, Ecological and evolutionary forces shaping microbial diversity in the human intestine, *Cell*, 124 (2006) 837-848.

- [103] G. J. Lieschke and N. S. Trede, Fish immunology, *Curr. Biol.*, 19 (2009) R678-R682.
- [104] S. Lipinski, A. Till, C. Sina, A. Arlt, H. Grasberger, S. Schreiber, and P. Rosenstiel, DUOX2-derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses, *J. Cell Sci.*, 122 (2009) 3522-3530.
- [105] M. A. Looijer-van Langen and L. A. Dieleman, Prebiotics in chronic intestinal inflammation, *Inflamm. Bowel. Dis.*, 15 (2009) 454-462.
- [106] C. A. Lozupone, J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight, Diversity, stability and resilience of the human gut microbiota, *Nature*, 489 (2012) 220-230.
- [107] C. Luci, A. Reynders, I. I. Ivanov, C. Cognet, L. Chiche, L. Chasson, J. Hardwigsen, E. Anguiano, J. Banchereau, D. Chaussabel, M. Dalod, D. R. Littman, E. Vivier, and E. Tomasello, Influence of the transcription factor RORgammat on the development of NKp46+ cell populations in gut and skin, *Nat. Immunol.*, 10 (2009) 75-82.
- [108] T. D. Luckey, Introduction to intestinal microecology, *Am. J. Clin. Nutr.*, 25 (1972) 1292-1294.
- [109] G. Lugo-Villarino, K. M. Balla, D. L. Stachura, K. Banuelos, M. B. Werneck, and D. Traver, Identification of dendritic antigen-presenting cells in the zebrafish, *Proc. Natl. Acad. Sci. U. S. A.*, 107 (2010) 15850-15855.
- [110] Q. Luo, P. Kumar, T. J. Vickers, A. Sheikh, W. G. Lewis, D. A. Rasko, J. Sistrunk, and J. M. Fleckenstein, Enterotoxigenic *Escherichia coli* secretes a highly conserved mucin-degrading metalloprotease to effectively engage intestinal epithelial cells, *Infect. Immun.*, 82 (2014) 509-521.
- [111] C. Lupp, M. L. Robertson, M. E. Wickham, I. Sekirov, O. L. Champion, E. C. Gaynor, and B. B. Finlay, Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of *Enterobacteriaceae*, *Cell Host. Microbe*, 2 (2007) 204.
- [112] A. J. Macpherson, D. Gatto, E. Sainsbury, G. R. Harriman, H. Hengartner, and R. M. Zinkernagel, A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria, *Science*, 288 (2000) 2222-2226.
- [113] A. J. Macpherson and E. Slack, The functional interactions of commensal bacteria with intestinal secretory IgA, *Curr. Opin. Gastroenterol.*, 23 (2007) 673-678.
- [114] A. J. Macpherson and T. Uhr, Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria, *Science*, 303 (2004) 1662-1665.

- [115] J. Mahdavi, B. Sonden, M. Hurtig, F. O. Olfat, L. Forsberg, N. Roche, J. Angstrom, T. Larsson, S. Teneberg, K. A. Karlsson, S. Altraja, T. Wadstrom, D. Kersulyte, D. E. Berg, A. DuBois, C. Petersson, K. E. Magnusson, T. Norberg, F. Lindh, B. B. Lundskog, A. Arnqvist, L. Hammarstrom, and T. Boren, *Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation, *Science*, 297 (2002) 573-578.
- [116] K. J. Maloy and F. Powrie, Intestinal homeostasis and its breakdown in inflammatory bowel disease, *Nature*, 474 (2011) 298-306.
- [117] R. Mandar and M. Mikelsaar, Transmission of mother's microflora to the newborn at birth, *Biol. Neonate*, 69 (1996) 30-35.
- [118] C. Manichanh, N. Borruel, F. Casellas, and F. Guarner, The gut microbiota in IBD, *Nat. Rev. Gastroenterol. Hepatol.*, 9 (2012) 599-608.
- [119] C. Manichanh, L. Rigottier-Gois, E. Bonnaud, K. Gloux, E. Pelletier, L. Frangeul, R. Nalin, C. Jarrin, P. Chardon, P. Marteau, J. Roca, and J. Dore, Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach, *Gut*, 55 (2006) 205-211.
- [120] J. G. Markle, D. N. Frank, S. Mortin-Toth, C. E. Robertson, L. M. Feazel, U. Rolle-Kampczyk, B. M. von, K. D. McCoy, A. J. Macpherson, and J. S. Danska, Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity, *Science*, 339 (2013) 1084-1088.
- [121] B. J. Marsland and E. S. Gollwitzer, Host-microorganism interactions in lung diseases, *Nat. Rev. Immunol.*, 14 (2014) 827-835.
- [122] M. Martinez-Medina, X. Aldeguer, M. Lopez-Siles, F. Gonzalez-Huix, C. Lopez-Oliu, G. Dahbi, J. E. Blanco, J. Blanco, L. J. Garcia-Gil, and A. Darfeuille-Michaud, Molecular diversity of *Escherichia coli* in the human gut: new ecological evidence supporting the role of adherent-invasive *E. coli* (AIEC) in Crohn's disease, *Inflamm. Bowel. Dis.*, 15 (2009) 872-882.
- [123] D. Mathis and C. Benoist, The influence of the microbiota on type-1 diabetes: on the threshold of a leap forward in our understanding, *Immunol. Rev.*, 245 (2012) 239-249.
- [124] C. L. Maynard, C. O. Elson, R. D. Hatton, and C. T. Weaver, Reciprocal interactions of the intestinal microbiota and immune system, *Nature*, 489 (2012) 231-241.
- [125] S. K. Mazmanian, J. L. Round, and D. L. Kasper, A microbial symbiosis factor prevents intestinal inflammatory disease, *Nature*, 453 (2008) 620-625.

- [126] J. R. McDermott, N. E. Humphreys, S. P. Forman, D. D. Donaldson, and R. K. Grencis, Intraepithelial NK cell-derived IL-13 induces intestinal pathology associated with nematode infection, *J. Immunol.*, 175 (2005) 3207-3213.
- [127] T. F. Meehan, D. A. Witherden, C. H. Kim, K. Sendaydiego, I. Ye, O. Garijo, H. K. Komori, A. Kumanogoh, H. Kikutani, L. Eckmann, and W. L. Havran, Protection against colitis by CD100-dependent modulation of intraepithelial gammadelta T lymphocyte function, *Mucosal. Immunol.*, 7 (2014) 134-142.
- [128] S. Meloni, G. Zarletti, S. Benedetti, E. Randelli, F. Buonocore, and G. Scapigliati, Cellular activities during a mixed leucocyte reaction in the teleost sea bass *Dicentrarchus labrax*, *Fish. Shellfish. Immunol.*, 20 (2006) 739-749.
- [129] A. L. Menke, J. M. Spitsbergen, A. P. Wolterbeek, and R. A. Woutersen, Normal anatomy and histology of the adult zebrafish, *Toxicol. Pathol.*, 39 (2011) 759-775.
- [130] U. Meyer-Hoffert, M. Hornef, B. Henriques-Normark, S. Normark, M. Andersson, and K. Putsep, Identification of heparin/heparan sulfate interacting protein as a major broad-spectrum antimicrobial protein in lung and small intestine, *FASEB J.*, 22 (2008) 2427-2434.
- [131] U. Meyer-Hoffert, M. W. Hornef, B. Henriques-Normark, L. G. Axelsson, T. Midtvedt, K. Putsep, and M. Andersson, Secreted enteric antimicrobial activity localises to the mucus surface layer, *Gut*, 57 (2008) 764-771.
- [132] S. Mitra, A. Alnabulsi, C. J. Secombes, and S. Bird, Identification and characterization of the transcription factors involved in T-cell development, t-bet, stat6 and foxp3, within the zebrafish, *Danio rerio*, *FEBS J.*, 277 (2010) 128-147.
- [133] P. Moayyedi, M. G. Surette, P. T. Kim, J. Libertucci, M. Wolfe, C. Onischi, D. Armstrong, J. K. Marshall, Z. Kassam, W. Reinisch, and C. H. Lee, Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial, *Gastroenterology*, 149 (2015) 102-109.
- [134] N. A. Molodecky, I. S. Soon, D. M. Rabi, W. A. Ghali, M. Ferris, G. Chernoff, E. I. Benchimol, R. Panaccione, S. Ghosh, H. W. Barkema, and G. G. Kaplan, Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review, *Gastroenterology*, 142 (2012) 46-54.
- [135] P. Mombaerts, E. Mizoguchi, M. J. Grusby, L. H. Glimcher, A. K. Bhan, and S. Tonegawa, Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice, *Cell*, 75 (1993) 274-282.
- [136] M. J. Morowitz, E. M. Carlisle, and J. C. Alverdy, Contributions of intestinal bacteria to nutrition and metabolism in the critically ill, *Surg. Clin. North Am.*, 91 (2011) 771-85, viii.

- [137] S. Mostowy, L. Boucontet, M. J. Mazon Moya, A. Sirianni, P. Boudinot, M. Hollinshead, P. Cossart, P. Herbolmel, J. P. Levraud, and E. Colucci-Guyon, The zebrafish as a new model for the in vivo study of *Shigella flexneri* interaction with phagocytes and bacterial autophagy, *PLoS. Pathog.*, 9 (2013) e1003588.
- [138] A. M. Mowat, Anatomical basis of tolerance and immunity to intestinal antigens, *Nat. Rev. Immunol.*, 3 (2003) 331-341.
- [139] A. M. Mowat and W. W. Agace, Regional specialization within the intestinal immune system, *Nat Rev. Immunol.*, 14 (2014) 667-685.
- [140] F. Navarro-Garcia, J. Gutierrez-Jimenez, C. Garcia-Tovar, L. A. Castro, H. Salazar-Gonzalez, and V. Cordova, Pic, an autotransporter protein secreted by different pathogens in the Enterobacteriaceae family, is a potent mucus secretagogue, *Infect. Immun.*, 78 (2010) 4101-4109.
- [141] T. L. Nguyen, S. Vieira-Silva, A. Liston, and J. Raes, How informative is the mouse for human gut microbiota research?, *Dis. Model. Mech.*, 8 (2015) 1-16.
- [142] J. H. Niess, S. Brand, X. Gu, L. Landsman, S. Jung, B. A. McCormick, J. M. Vyas, M. Boes, H. L. Ploegh, J. G. Fox, D. R. Littman, and H. C. Reinecker, CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance, *Science*, 307 (2005) 254-258.
- [143] J. M. Norman, S. A. Handley, M. T. Baldridge, L. Droit, C. Y. Liu, B. C. Keller, A. Kambal, C. L. Monaco, G. Zhao, P. Fleshner, T. S. Stappenbeck, D. P. McGovern, A. Keshavarzian, E. A. Mutlu, J. Sauk, D. Gevers, R. J. Xavier, D. Wang, M. Parkes, and H. W. Virgin, Disease-specific alterations in the enteric virome in inflammatory bowel disease, *Cell*, 160 (2015) 447-460.
- [144] M. Novinec and B. Lenarcic, Cathepsin K: a unique collagenolytic cysteine peptidase, *Biol. Chem.*, 394 (2013) 1163-1179.
- [145] A. M. O'Hara and F. Shanahan, The gut flora as a forgotten organ, *EMBO Rep.*, 7 (2006) 688-693.
- [146] S. H. Oehlers, M. V. Flores, C. J. Hall, K. E. Crosier, and P. S. Crosier, Retinoic acid suppresses intestinal mucus production and exacerbates experimental enterocolitis, *Dis. Model. Mech.*, 5 (2012) 457-467.
- [147] S. H. Oehlers, M. V. Flores, C. J. Hall, S. Swift, K. E. Crosier, and P. S. Crosier, The inflammatory bowel disease (IBD) susceptibility genes NOD1 and NOD2 have conserved anti-bacterial roles in zebrafish, *Dis. Model. Mech.*, 4 (2011) 832-841.
- [148] N. Ohkura, Y. Kitagawa, and S. Sakaguchi, Development and maintenance of regulatory T cells, *Immunity*, 38 (2013) 414-423.

- [149] C. Palmer, E. M. Bik, D. B. DiGiulio, D. A. Relman, and P. O. Brown, Development of the human infant intestinal microbiota, *PLoS. Biol.*, 5 (2007) e177.
- [150] T. Pelaseyed, J. H. Bergstrom, J. K. Gustafsson, A. Ermund, G. M. Birchenough, A. Schutte, S. van der Post, F. Svensson, A. M. Rodriguez-Pineiro, E. E. Nystrom, C. Wising, M. E. Johansson, and G. C. Hansson, The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system, *Immunol. Rev.*, 260 (2014) 8-20.
- [151] D. A. Peterson, D. N. Frank, N. R. Pace, and J. I. Gordon, Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases, *Cell Host. Microbe*, 3 (2008) 417-427.
- [152] D. A. Peterson, N. P. McNulty, J. L. Guruge, and J. I. Gordon, IgA response to symbiotic bacteria as a mediator of gut homeostasis, *Cell Host. Microbe*, 2 (2007) 328-339.
- [153] T. Petnicki-Ocwieja, T. Hrnčir, Y. J. Liu, A. Biswas, T. Hudcovic, H. Tlaskalova-Hogenova, and K. S. Kobayashi, Nod2 is required for the regulation of commensal microbiota in the intestine, *Proc. Natl. Acad. Sci. U. S. A.*, 106 (2009) 15813-15818.
- [154] F. Powrie, M. W. Leach, S. Mauze, L. B. Caddle, and R. L. Coffman, Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice, *Int. Immunol.*, 5 (1993) 1461-1471.
- [155] G. A. Preidis and J. Versalovic, Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era, *Gastroenterology*, 136 (2009) 2015-2031.
- [156] K. Putsep, L. G. Axelsson, A. Boman, T. Midtvedt, S. Normark, H. G. Boman, and M. Andersson, Germ-free and colonized mice generate the same products from enteric prodefensins, *J. Biol. Chem.*, 275 (2000) 40478-40482.
- [157] F. J. Quintana, A. H. Iglesias, M. F. Farez, M. Caccamo, E. J. Burns, N. Kassam, M. Oukka, and H. L. Weiner, Adaptive autoimmunity and Foxp3-based immunoregulation in zebrafish, *PLoS. One.*, 5 (2010) e9478.
- [158] M. Raffatellu and A. J. Baumler, *Salmonella*'s iron armor for battling the host and its microbiota, *Gut Microbes.*, 1 (2010) 70-72.
- [159] S. Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, and R. Medzhitov, Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis, *Cell*, 118 (2004) 229-241.

- [160] J. F. Rawls, M. A. Mahowald, R. E. Ley, and J. I. Gordon, Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection, *Cell*, 127 (2006) 423-433.
- [161] J. F. Rawls, B. S. Samuel, and J. I. Gordon, Gnotobiotic zebrafish reveal evolutionarily conserved responses to the gut microbiota, *Proc. Natl. Acad. Sci. U. S. A.*, 101 (2004) 4596-4601.
- [162] A. Rehman, P. Lepage, A. Nolte, S. Hellmig, S. Schreiber, and S. J. Ott, Transcriptional activity of the dominant gut mucosal microbiota in chronic inflammatory bowel disease patients, *J. Med. Microbiol.*, 59 (2010) 1114-1122.
- [163] Reinoso, Webb C. and Grisham, M. B. Pharmacological Intervention Studies Using Mouse Models of chronic intestinal inflammation. In press. 2015.
- [164] M. Rescigno, M. Urbano, B. Valzasina, M. Francolini, G. Rotta, R. Bonasio, F. Granucci, J. P. Kraehenbuhl, and P. Ricciardi-Castagnoli, Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria, *Nat. Immunol.*, 2 (2001) 361-367.
- [165] A. Reynders, N. Yessaad, T. P. Vu Manh, M. Dalod, A. Fenis, C. Aubry, G. Nikitas, B. Escaliere, J. C. Renauld, O. Dussurget, P. Cossart, M. Lecuit, E. Vivier, and E. Tomasello, Identity, regulation and in vivo function of gut NKp46+RORgammat+ and NKp46+RORgammat- lymphoid cells, *EMBO J.*, 30 (2011) 2934-2947.
- [166] G. Roeselers, E. K. Mittge, W. Z. Stephens, D. M. Parichy, C. M. Cavanaugh, K. Guillemin, and J. F. Rawls, Evidence for a core gut microbiota in the zebrafish, *ISME. J.*, 5 (2011) 1595-1608.
- [167] J. H. Rombout, L. Abelli, S. Picchietti, G. Scapigliati, and V. Kiron, Teleost intestinal immunology, *Fish. Shellfish. Immunol.*, 31 (2011) 616-626.
- [168] A. Rongvaux, H. Takizawa, T. Strowig, T. Willinger, E. E. Eynon, R. A. Flavell, and M. G. Manz, Human hemato-lymphoid system mice: current use and future potential for medicine, *Annu. Rev. Immunol.*, 31 (2013) 635-674.
- [169] Rosner, J. L. Ten times more microbial cells than body cells in humans? *Microbe* 9, 47. 2014.
- [170] N. G. Rossen, S. Fuentes, M. J. van der Spek, J. G. Tijssen, J. H. Hartman, A. Duflou, M. Lowenberg, G. R. van den Brink, E. M. Mathus-Vliegen, W. M. de Vos, E. G. Zoetendal, G. R. D'Haens, and C. Y. Ponsioen, Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis, *Gastroenterology*, 149 (2015) 110-118.

- [171] J. L. Round and S. K. Mazmanian, The gut microbiota shapes intestinal immune responses during health and disease, *Nat. Rev. Immunol.*, 9 (2009) 313-323.
- [172] P. Rutgeerts, K. Goobes, M. Peeters, M. Hiele, F. Penninckx, R. Aerts, R. Kerremans, and G. Vantrappen, Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum, *Lancet*, 338 (1991) 771-774.
- [173] B. Sadlack, H. Merz, H. Schorle, A. Schimpl, A. C. Feller, and I. Horak, Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene, *Cell*, 75 (1993) 253-261.
- [174] S. L. Sanos, V. L. Bui, A. Mortha, K. Oberle, C. Heners, C. Johnner, and A. Diefenbach, RORgammat and commensal microflora are required for the differentiation of mucosal interleukin 22-producing NKp46+ cells, *Nat. Immunol.*, 10 (2009) 83-91.
- [175] P. J. Sansonetti, To be or not to be a pathogen: that is the mucosally relevant question, *Mucosal. Immunol.*, 4 (2011) 8-14.
- [176] R. B. Sartor, Microbial influences in inflammatory bowel diseases, *Gastroenterology*, 134 (2008) 577-594.
- [177] N. Satoh-Takayama, C. A. Vosshenrich, S. Lesjean-Pottier, S. Sawa, M. Lochner, F. Rattis, J. J. Mention, K. Thiam, N. Cerf-Bensussan, O. Mandelboim, G. Eberl, and J. P. Di Santo, Microbial flora drives interleukin 22 production in intestinal NKp46+ cells that provide innate mucosal immune defense, *Immunity*, 29 (2008) 958-970.
- [178] D. C. Savage, Microbial ecology of the gastrointestinal tract, *Annu. Rev. Microbiol.*, 31 (1977) 107-133.
- [179] M. Schenk and C. Mueller, Adaptations of intestinal macrophages to an antigen-rich environment, *Semin. Immunol.*, 19 (2007) 84-93.
- [180] H. Seedorf, N. W. Griffin, V. K. Ridaura, A. Reyes, J. Cheng, F. E. Rey, M. I. Smith, G. M. Simon, R. H. Scheffrahn, D. Woebken, A. M. Spormann, T. W. Van, L. K. Ursell, M. Pirrung, A. Robbins-Pianka, B. L. Cantarel, V. Lombard, B. Henrissat, R. Knight, and J. I. Gordon, Bacteria from diverse habitats colonize and compete in the mouse gut, *Cell*, 159 (2014) 253-266.
- [181] H. Seno, H. Miyoshi, S. L. Brown, M. J. Geske, M. Colonna, and T. S. Stappenbeck, Efficient colonic mucosal wound repair requires Trem2 signaling, *Proc. Natl. Acad. Sci. U. S. A.*, 106 (2009) 256-261.
- [182] M. Shale, C. Schiering, and F. Powrie, CD4(+) T-cell subsets in intestinal inflammation, *Immunol. Rev.*, 252 (2013) 164-182.

- [183] M. T. Shanahan, H. Tanabe, and A. J. Ouellette, Strain-specific polymorphisms in Paneth cell alpha-defensins of C57BL/6 mice and evidence of vestigial myeloid alpha-defensin pseudogenes, *Infect. Immun.*, 79 (2011) 459-473.
- [184] C. Sina, S. Lipinski, O. Gavrilova, K. Aden, A. Rehman, A. Till, A. Rittger, R. Podschun, U. Meyer-Hoffert, R. Haesler, E. Midtling, K. Putsep, M. A. McGuckin, S. Schreiber, P. Saftig, and P. Rosenstiel, Extracellular cathepsin K exerts antimicrobial activity and is protective against chronic intestinal inflammation in mice, *Gut*, 62 (2013) 520-530.
- [185] E. Slack, M. L. Balmer, and A. J. Macpherson, B cells as a critical node in the microbiota-host immune system network, *Immunol. Rev.*, 260 (2014) 50-66.
- [186] P. D. Smith, L. E. Smythies, R. Shen, T. Greenwell-Wild, M. Gliozzi, and S. M. Wahl, Intestinal macrophages and response to microbial encroachment, *Mucosal. Immunol.*, 4 (2011) 31-42.
- [187] S. Smriga, S. A. Sandin, and F. Azam, Abundance, diversity, and activity of microbial assemblages associated with coral reef fish guts and feces, *FEMS Microbiol. Ecol.*, 73 (2010) 31-42.
- [188] L. E. Smythies, M. Sellers, R. H. Clements, M. Mosteller-Barnum, G. Meng, W. H. Benjamin, J. M. Orenstein, and P. D. Smith, Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity, *J. Clin. Invest.*, 115 (2005) 66-75.
- [189] L. E. Smythies, R. Shen, D. Bimczok, L. Novak, R. H. Clements, D. E. Eckhoff, P. Bouchard, M. D. George, W. K. Hu, S. Dandekar, and P. D. Smith, Inflammation anergy in human intestinal macrophages is due to Smad-induced IkappaBalpha expression and NF-kappaB inactivation, *J. Biol. Chem.*, 285 (2010) 19593-19604.
- [190] G. Solis, de los Reyes-Gavilan CG, N. Fernandez, A. Margolles, and M. Gueimonde, Establishment and development of lactic acid bacteria and bifidobacteria microbiota in breast-milk and the infant gut, *Anaerobe.*, 16 (2010) 307-310.
- [191] G. F. Sonnenberg, L. A. Monticelli, T. Alenghat, T. C. Fung, N. A. Hutnick, J. Kunisawa, N. Shibata, S. Grunberg, R. Sinha, A. M. Zahm, M. R. Tardif, T. Sathaliyawala, M. Kubota, D. L. Farber, R. G. Collman, A. Shaked, L. A. Fouser, D. B. Weiner, P. A. Tessier, J. R. Friedman, H. Kiyono, F. D. Bushman, K. M. Chang, and D. Artis, Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria, *Science*, 336 (2012) 1321-1325.
- [192] A. Spor, O. Koren, and R. Ley, Unravelling the effects of the environment and host genotype on the gut microbiome, *Nat. Rev. Microbiol.*, 9 (2011) 279-290.

- [193] B. Stecher, S. Hapfelmeier, C. Muller, M. Kremer, T. Stallmach, and W. D. Hardt, Flagella and chemotaxis are required for efficient induction of *Salmonella enterica* serovar Typhimurium colitis in streptomycin-pretreated mice, *Infect. Immun.*, 72 (2004) 4138-4150.
- [194] A. Suau, R. Bonnet, M. Sutren, J. J. Godon, G. R. Gibson, M. D. Collins, and J. Dore, Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut, *Appl. Environ. Microbiol.*, 65 (1999) 4799-4807.
- [195] K. E. Sullam, S. D. Essinger, C. A. Lozupone, M. P. O'Connor, G. L. Rosen, R. Knight, S. S. Kilham, and J. A. Russell, Environmental and ecological factors that shape the gut bacterial communities of fish: a meta-analysis, *Mol. Ecol.*, 21 (2012) 3363-3378.
- [196] F. Takizawa, J. M. Dijkstra, P. Kotterba, T. Korytar, H. Kock, B. Kollner, B. Jaureguiberry, T. Nakanishi, and U. Fischer, The expression of CD8alpha discriminates distinct T cell subsets in teleost fish, *Dev. Comp Immunol.*, 35 (2011) 752-763.
- [197] K. J. Thorne, R. C. Oliver, and A. J. Barrett, Lysis and killing of bacteria by lysosomal proteinases, *Infect. Immun.*, 14 (1976) 555-563.
- [198] M. C. Toh, M. Goodyear, M. Daigneault, E. Allen-Vercoe, and T. J. Van Raay, Colonizing the embryonic zebrafish gut with anaerobic bacteria derived from the human gastrointestinal tract, *Zebrafish.*, 10 (2013) 194-198.
- [199] D. M. Underhill and I. D. Iliev, The mycobiota: interactions between commensal fungi and the host immune system, *Nat Rev. Immunol.*, 14 (2014) 405-416.
- [200] V. Valatas, M. Vakas, and G. Kolios, The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases, *Am. J. Physiol Gastrointest. Liver Physiol*, 305 (2013) G763-G785.
- [201] M. van der Sluis, J. Bouma, A. Vincent, A. Velcich, K. L. Carraway, H. A. Buller, A. W. Einerhand, J. B. van Goudoever, S. Van, I, I. B. Renes, Combined defects in epithelial and immunoregulatory factors exacerbate the pathogenesis of inflammation: mucin 2-interleukin 10-deficient mice, *Lab Invest*, 88 (2008) 634-642.
- [202] M. van der Sluis, B. A. de Koning, A. C. De Bruijn, A. Velcich, J. P. Meijerink, J. B. van Goudoever, H. A. Buller, J. Dekker, S. Van, I, I. B. Renes, and A. W. Einerhand, Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection, *Gastroenterology*, 131 (2006) 117-129.
- [203] d. van, V, H. P. Spaink, and A. H. Meijer, Pathogen recognition and activation of the innate immune response in zebrafish, *Adv. Hematol.*, 2012 (2012) 159807.

- [204] d. van, V, J. J. van Soest, H. P. Spalink, and A. H. Meijer, Functional analysis of a zebrafish myd88 mutant identifies key transcriptional components of the innate immune system, *Dis. Model. Mech.*, 6 (2013) 841-854.
- [205] N. E. van, A. Vrieze, M. Nieuwdorp, S. Fuentes, E. G. Zoetendal, W. M. de Vos, C. E. Visser, E. J. Kuijper, J. F. Bartelsman, J. G. Tijssen, P. Speelman, M. G. Dijkgraaf, and J. J. Keller, Duodenal infusion of donor feces for recurrent *Clostridium difficile*, *N. Engl. J. Med.*, 368 (2013) 407-415.
- [206] N. T. Ventham, N. A. Kennedy, E. R. Nimmo, and J. Satsangi, Beyond Gene Discovery in Inflammatory Bowel Disease: The Emerging Role of Epigenetics, *Gastroenterology*, (2013).
- [207] A. W. Walker and T. D. Lawley, Therapeutic modulation of intestinal dysbiosis, *Pharmacol. Res.*, 69 (2013) 75-86.
- [208] K. N. Wallace, S. Akhter, E. M. Smith, K. Lorent, and M. Pack, Intestinal growth and differentiation in zebrafish, *Mech. Dev.*, 122 (2005) 157-173.
- [209] Z. Wang, J. Du, S. H. Lam, S. Mathavan, P. Matsudaira, and Z. Gong, Morphological and molecular evidence for functional organization along the rostrocaudal axis of the adult zebrafish intestine, *BMC. Genomics*, 11 (2010) 392.
- [210] B. Weigmann, N. Schughart, C. Wiebe, S. Sudowe, H. A. Lehr, H. Jonuleit, L. Vogel, C. Becker, M. F. Neurath, S. Grabbe, J. Saloga, and I. Bellinghausen, Allergen-induced IgE-dependent gut inflammation in a human PBMC-engrafted murine model of allergy, *The Journal of allergy and clinical immunology*, 129 (2012) 1126-1135.
- [211] W. B. Whitman, D. C. Coleman, and W. J. Wiebe, Prokaryotes: the unseen majority, *Proc. Natl. Acad. Sci. U. S. A.*, 95 (1998) 6578-6583.
- [212] S. E. Winter and A. J. Baumler, Dysbiosis in the inflamed intestine: chance favors the prepared microbe, *Gut Microbes.*, 5 (2014) 71-73.
- [213] S. E. Winter, C. A. Lopez, and A. J. Baumler, The dynamics of gut-associated microbial communities during inflammation, *EMBO Rep.*, 14 (2013) 319-327.
- [214] M. Wlodarska, A. D. Kostic, and R. J. Xavier, An integrative view of microbiome-host interactions in inflammatory bowel diseases, *Cell Host. Microbe*, 17 (2015) 577-591.
- [215] H. Wu, E. Santoni-Rugiu, E. Ralfkiaer, B. T. Porse, C. Moser, N. Hoiby, N. Borregaard, and J. B. Cowland, Lipocalin 2 is protective against *E. coli* pneumonia, *Respir. Res.*, 11 (2010) 96.

- 1
2
3
4 [216] Y. Yang, S. Tomkovich, and C. Jobin, Could a swimming creature inform us on
5 intestinal diseases? Lessons from zebrafish, *Inflamm. Bowel. Dis.*, 20 (2014)
6 956-966.
7
8
9 [217] T. Yatsunenko, F. E. Rey, M. J. Manary, I. Trehan, M. G. Dominguez-Bello, M.
10 Contreras, M. Magris, G. Hidalgo, R. N. Baldassano, A. P. Anokhin, A. C. Heath,
11 B. Warner, J. Reeder, J. Kuczynski, J. G. Caporaso, C. A. Lozupone, C. Lauber,
12 J. C. Clemente, D. Knights, R. Knight, and J. I. Gordon, Human gut microbiome
13 viewed across age and geography, *Nature*, 486 (2012) 222-227.
14
15
16 [218] J. A. Yoder, Form, function and phylogenetics of NITRs in bony fish, *Dev. Comp*
17 *Immunol.*, 33 (2009) 135-144.
18
19 [219] S. W. Zac, A. R. Burns, K. Stagaman, S. Wong, J. F. Rawls, K. Guillemin, and B.
20 J. Bohannon, The composition of the zebrafish intestinal microbial community
21 varies across development, *ISME. J.*, (2015).
22
23
24 [220] L. A. Zenewicz, G. D. Yancopoulos, D. M. Valenzuela, A. J. Murphy, S. Stevens,
25 and R. A. Flavell, Innate and adaptive interleukin-22 protects mice from
26 inflammatory bowel disease, *Immunity.*, 29 (2008) 947-957.
27
28
29 [221] Y. A. Zhang, I. Salinas, J. Li, D. Parra, S. Bjork, Z. Xu, S. E. LaPatra, J.
30 Bartholomew, and J. O. Sunyer, IgT, a primitive immunoglobulin class
31 specialized in mucosal immunity, *Nat. Immunol.*, 11 (2010) 827-835.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 1

Human

■ Firmicutes
■ Bacteroidetes
■ Actinobacteria
■ Proteobacteria

Mouse

■ Firmicutes
■ Bacteroidetes
■ Tenericutes
■ Proteobacteria
■ Thermotogae
■ Other

Zebrafish

■ Proteobacteria
■ Fusobacteria
■ Firmicutes
■ Bacteroidetes

Figure 1. Relative abundance of the major intestinal phyla in humans, mice and zebrafish. Deep sequencing of 16S rRNA gene reveals that while the relative abundance of specific bacterial phyla may differ, mammals and teleosts possess similar bacterial communities. Human and zebrafish pie charts were derived from [121,166], respectively (with permission). Mouse pie chart was generated from colonic luminal contents of healthy C57Bl/6 mice housed at the TTUHSC animal facility (unpublished data).

Figure 2

Figure 2. Spatial organization of microbial communities and physiological gradients along the mammalian gastrointestinal tract. The numbers and types of bacterial communities, as well as physiological factors vary along the length of the gastrointestinal (GI) tract. It is well-appreciated that the oxygen levels, bile acid concentrations, intestinal motility, antimicrobial peptides (AMPs) and luminal pH in proximal portion of the GI tract (stomach, duodenum, jejunum) play major roles in restricting the numbers and types of microorganisms. In general, aerobic and facultative anaerobic bacteria are found almost exclusively in the proximal portion of the GI tract. The hypoxic nature and more physiological pH of the distal small intestine (ileum) and colon coupled to overall reductions of bile acids, AMPs and gut motility, allows for unfettered growth of large numbers of obligate anaerobic bacteria. These oxygen-sensitive microbes are capable of producing large quantities of short chain fatty acids (SCFAs; acetate, propionate, butyrate) from complex carbohydrates (fiber) to be used for important colonic and immunologic processes. Figure derived from [38,139,214]. The anatomical structure of the gastrointestinal tract with associated microbial communities and bacterial load were reproduced from reference 139 with permission.